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  Materials and Methods 
Computational de novo protein design of ACE2 decoys 
Spike protein RBD-binding motifs interacting with ACE2 were identified and extracted           
from publicly available structures (PDBs: 6CS2, 6VW1, 6M17); one (H1) spanning residues            
19-53; another (H2) spanning residues 55-84; and in some designs, a third beta-hairpin motif              
(EE3) spanning residues 346-360. The surface-exposed residues from these motifs (ACE2           
residue numbers 19, 23, 24, 27, 28, 30, 31, 34, 35, 37, 38, 41, 42 and 45 from H1; 61, 64, 68, 72,                       
75, 76, 79, 82 and 83 from H2; and 352, 353, 354, 355 and 357 from EE3, if present) were                    
preserved, and the buried residues were allowed to change. The supporting structures were either              
computationally generated and placed by an available method (e.g. Rosetta combinatorial           
fragment assembly, parametric generation, etc) or extracted from existing structures. The           
position and orientation of the new elements was refined using a monte carlo search to optimize                
core packing. This protocol which idealized the motifs and generated fully-connected backbones            
using a clustered database of known protein structure fragments. A total of 34,589 designs were               
generated and filtered based on computational metrics. Of the designs that passed the filters,              
biased forward folding simulations (see below) were run on 1,899 designs to eliminate designs to               
study the global energy minima. Of the designs that passed the filters, 196 were ordered from                
four the sets of top-ranked designs in: 1) Rosetta score per residue; 2) biased folding simulations;                
3) ddG as computed using Rosetta. In addition, a set of hand-selected designs were synthesized               
and screened. First, the core elements (i.e., the starting motifs and supporting secondary             
structure) were rebuilt by identifying parametric equations of repetitive phi and psi angles             
(omega fixed to 180°) that result in secondary structures that recapitulated each of the target               
helices as close as possible, a “pitch” on the phi and psi angles was allowed every 3rd residue in                   
order to allow the helices the possibility to have curvature. By using these parametric equations,               
the algorithm can vary the length of each of the core-elements up to +/- 12 amino acids                 
(compared to the input structural motifs). All length variations of the core-elements were then              
reconnected pairwise with loops from a clustered database of highly ideal loops (fragment-size             
of 7 amino acids). To connect pairs of secondary structure elements, the mimetic building              
protocol aims to reconnect the idealized elements by pairs in all possible combinations. For each               
pair of secondary structure elements, the loop database was filtered to remove.  
The databases of highly ideal fragments used for the design of the backbones for the de                
novo mimetics were constructed with the Rosetta application        
“kcenters_clustering_of_fragments” using an extensive database of non-redundant (publicly        
available) protein structures from the RCSB protein data bank, which was comprised of 7062              
PDBs for the 7-mer database.  
Folding simulations were biased towards the designed conformation ​(​49​) by using a small             
subset of fragments at each residue position with the lowest RMSD (9- and 3-mers) to the                
designed structure. The funnel-shaped energy landscape suggests that the designed structure is            
the global energy minima and has a substantial energy gap with respect to alternative              
conformations. In the plots shown for the simulations, each dot represents an independent biased              
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forward folding trajectory which was computed by monte carlo insertion of fragments from             
solved protein structures. Three sets of trajectories are computed; those using only the 5              
fragments with lowest RMSD to the design (brown), those using fragments from the design              
model plus the 8 fragments with lowest RMSD (orange) and relax trajectories (blue). 
Sequence and structural alignment to natural proteins 
The CTC-445.2 design model was structurally aligned to the NCBI nr-PDB database of             
non-redundant PDB chains ​(​50​)​; p-value cutoff of 1e-7). Sequential structural alignment was            
performed using TMalign with the default options. MICAN alignment ​(​51​) was used for inverse,              
Ca-only, alternative, and non-sequential structural alignments (flags=”-n 1 -r”). TMscores ​(​52​,           
53​) were normalized to CTC-445.2 and sequence identities were computed using only the             
structurally aligned residues. Alignments with less than 79 amino acids (the total length of the               
RBD-binding ACE2 motifs used to seed the designs) were discarded. 
Yeast display screening 
Genes encoding ​de novo ACE2 decoys and hACE2 were ordered as gBlocks (IDT), with 60               
bases of overlap on each end to the pETcon3 yeast display plasmid. gBlocks and linearized               
pETcon3 (digested with NdeI and XhoI restriction enzymes and purified by gel extraction) were              
transformed together into ​S. cerevisiae ​strain EBY100 cells. Via homologous recombination, the            
genes for the designed proteins were placed in frame between the ​AGA2 ​gene and the Myc tag on                  
the plasmid, to allow protein expression on the surface of yeast with a c-terminal Myc tag. Yeast                 
were first grown in C-Trp-Ura selective media to saturation, and later induced for 12-18 h in                
SGCAA media. Cells were then first washed with chilled PBSF buffer (50 mM NaPO​4​, 150 mM                
NaCl, 0.1% w/v BSA, pH 7.4), and allowed to bind to 200 nM SARS-CoV-2 Spike RBD-mFc                
(Sino Biological; residues Arg319-Phe541), for 30 min on ice. Cells were washed with chilled              
PBSF buffer again, and tagged with FITC-conjugated chicken anti-cMyc antibody (ICL           
#CMYC-45F, Immunology Consultants Laboratory, Inc, Lake Oswego, OR, USA), at 0.8 µL per             
10​6 cells, and phycoerythrin-conjugated goat anti-mFc antibody (#115-116-071, RRID:         
AB_2338626, Jackson ImmunoResearch, West Grove, PA, USA), at 1.6 µL per 10​6 cells, for 15               
min on ice, and washed again with chilled PBSF buffer. Lastly, cells were analyzed by flow                
cytometry using the Guava easyCyte flow cytometer. 
To characterize the binding affinity and competition to hACE2 of CTC-445, yeast display             
assays were performed as described above, using varying amounts of SARS-CoV-2 Spike            
RBD-mFc (0-243 nM) for the titration assay and 9 nM SARS-CoV-2 Spike RBD-mFc with              
varying concentrations of soluble human ACE2 His-tag (Sino Biological; residues Met1-Ser740)           
(0-729 nM) for the competition assay. 
Directed evolution 
Error prone PCRs (epPCR) of the gene coding for CTC-445 were performed using a              
GeneMorph II Random Mutagenesis Kit (Agilent), according to the standard protocol. Two            
separate PCR reactions were performed using 10 ng and 1 ng of the CTC-445-coding gene as the                 
initial target DNA, in order to obtain a higher and lower error rate pool. Amplification was                
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performed with the pETCON_overlap_fwd    
(AGTGGTGGAGGAGGCTCTGGTGGAGGCGGTAGCGGAGGCGGAGGGTCGGCTAGCC
ATATG) and pETCON_overlap_rev   
(AGATCTCTATTACAAGTCCTCTTCAGAAATAAGCTTTTGTTCGGATCCGCCCCCCTC
GAG) primers. Thirty cycles of amplification were used for the PCR, with an annealing              
temperature of 55°C. The products of both PCRs were combined, and purified by ethanol              
precipitation. 12 µg of CTC-445 epPCR DNA, together with 4 µg of linearized pETcon3 vector,               
were transformed by electroporation into conditioned ​S. cerevisiae ​strain EBY100 cells. The            
transformation efficiency was 2x10​6​ transformants. 
Six rounds of cell sorting were performed on the library of CTC-445 epPCR, to identify               
mutations that improve binding to SARS-CoV-2 and improve its stability to proteases. Yeast             
were grown in C-Trp-Ura selective media and later induced for 12-18 h in SGCAA media. Cells                
were pretreated before primary labeling with a mixture of trypsin (12.5 µg/mL) and             
chymotrypsin (5 µg/mL) in TBS buffer (25 mM Tris-HCl, 150 mM NaCl, pH 8.0) for 5 min at                  
room temperature. This reaction was halted by adding a large excess volume of ice-cold TBSF               
1% (25 mM Tris-HCl, 150 mM NaCl, 1% w/v BSA, pH 8.0) and washing the cells four                 
additional times with TBSF 1%. Cells were then labelled with ​decreasing concentrations of             
SARS-CoV-2 Spike RBD-mFc at every round of sorting: ​200 nM (round 1, 10​8 cells sorted), 10                
nM (round 2, 10​7 cells sorted), 1 nM (round 3, 10​6 cells sorted), 100 pM (round 4, 10​6 cells                   
sorted), 10 pM (round 5, 10​6 cells sorted) and 1 pM (round 6, 10​6 cells sorted)​, for 30 min on ice,                     
and washed with chilled PBSF buffer. Starting at sorting round 4, an additional selection step for                
improved k​off was added, where cells were incubated in 1 ml PBSF buffer at 37 °C for 1 hour,                   
and washed again with chilled PBSF buffer. Lastly, cells were incubated with FITC-conjugated             
chicken anti-cMyc antibody (ICL #CMYC-45F, Immunology Consultants Laboratory, Inc, Lake          
Oswego, OR​), at 0.3 ​μ​L per 10​6 cells for sorts 1 and 2, and 3 ​μ​L per 10​6 cells for remaining sorts                      
and phycoerythrin-conjugated goat anti-mFc antibody (​#115-116-071, RRID: AB_2338626,        
Jackson ImmunoResearch, West Grove, PA, USA), at 0.4 ​μ​L per 10​6 cells for sorts 1 and 2, and                  
4 ​μ​L per 10​6 cells for remaining sorts, for 15 min on ice, and washed again with chilled PBSF                   
buffer. ​Fluorescence-activated cell sorting (FACS) was performed with the Sony SH800           
instrument, selecting the top 5% of the displaying subpopulation by their PE/FITC fluorescence             
ratios. Lastly, selected cells were plated on SDCAA agar plates and single colonies were picked,               
amplified by PCR, and sequenced by Sanger sequencing (Genewiz). 
Cloning and molecular biology 
The dsDNA CTC-445 gBlock with pETcon3 overlaps (5’ overlap:         
5’-gctagtggtggaggaggctctggtggaggcggtagcggaggcggagggtcggctagccatatg-3’, 3’ overlap:   
5’-ctcgaggggggcggatccgaacaaaagcttatttctgaagaggacttgtaatagagatct-3’) was digested with NdeI     
and XhoI endonucleases (New England Biolabs) for 1 hour at 37°C followed by ligation into               
linear pET29b(+) using T4 DNA Ligase (New England Biolabs). The vector was linearized by              
100-fold overdigestion by NdeI and XhoI and then purified by gel extraction (Qiagen). For the               
optimized CTC-445 variants, genes with overlaps for pET29b(+) (5’:         
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AAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATG, 3’:  
CTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTA) were designed, ordered and     
cloned by overlap extension or Gibson assembly ​(​54​)​. To facilitate protein quantification, and to              
enable cleavage of the C-terminal His tag, a C-terminal GSGWGSGLVPRGS sequence was            
added to all CTC-445-derived sequences. 
Recombinant protein expression 
Protein sequences were synthesized (IDT) and cloned into pET-29b(+) E. coli plasmid            
expression vectors (both with and without a thrombin-cleavable C-terminal 6-His tag). Plasmids            
containing the clones of CTC-445, one non-expressing negative control and a positive control             
protein transformed into chemically competent E. coli Lemo21 cells (NEB). Protein expression            
was then induced with 1 mM of isopropyl β-d-thiogalactopyranoside (IPTG) at 37 °C. After 4 h                
expression, samples were collected and run on SDS-PAGE gel along with a PageRuler Plus              
Prestained Protein Ladder. 
Chemical protein denaturation 
Samples of CTC-445, CTC-445.2 and CTC-445.2d were incubated overnight at 1 mg/mL            
with 0-6 M guanidinium chloride in PBS buffer (pH 7.4). Circular dichroism spectra were              
measured for each sample at 25 °C in a 0.1 mm path-length cuvette using an Chirascan                
spectropolarimeter V100 (Applied Photophysics). The unfolding curve at 222 nm was fitted to             
the following equation:  
D  f =
1+ exp +exp( −( RTΔGND − mND GuHCl[ ]) −( RTΔGID − mID GuHCl[ ])   )
(yN+mN GuHCl )+(yD+mD GuHCl ) exp +(yI+mI GuHCl ) exp( [ ] [ ] * −( RTΔGND−mND GuHCl[ ]) [ ] * −( RTGID−mID GuHCl[ ]))
 
Where fD is the fraction of protein in the unfolded state, yN, yI and yD are the signals of                   
the native, intermediate and unfolding states, mN, mI and mD represent the signal dependence              
with the denaturant concentration, ΔGND and ΔGID are the free energy changes for the native               
and intermediate states while mND and mID represent their dependence with de denaturant             
concentration. Finally, R represents the gas constant in kcal mol​-1 K​-1 and T the temperature in K.                 
ΔGNI is calculated from the subtraction of ΔGID to ΔGND.  
Circular dichroism 
Far-ultraviolet circular dichroism measurements were carried out for de novo decoys and            
hACE2 (Sino Biological, Cat#40592-V08B-B) with an CHIRASCAN spectrometer V100         
(Applied Photophysics) in PBS buffer (pH 7.4) in a 0.1 mm path-length cuvette with protein               
concentration of 0.2 mg/mL (unless otherwise mentioned in the text). Temperature melts were             
obtained from 20 to 95 °C and monitored absorption signal at 222 nm (steps of 0.5 °C per min,                   
30 s of equilibration by step). Wavelength scans (195–250 nm) were collected at 20 °C, 95 °C,                 
and again at 20 °C after refolding (roughly 5 min). Melting temperature (Tm) values were               
calculated from the fitting of the thermal melts to the following equation: 
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Df =
1+exp( −[ RΔHvH ( 1T 1T m)])
(yN+mNT )+(yD+mDT ) exp( * −[ RΔHvH ( 1T 1T m)])
 
Where fD is the fraction of the protein in the unfolded state, HvH is the enthalpy change                  
associated to the unfolding process, yN and mN represent the signal of the native state and its                 
dependence with the temperature, yD and mD represent the signal of the unfolded state and is                
dependence with the temperature and R is the gas constant. 
Serial thermal ramping protein stability 
Serial thermal ramping assays were performed in order to test the unfolding reversibility             
(thermal recovery) of CTC-445, CTC-445.2, CTC-445.2d and hACE2 (Sino Biological,          
Cat#40592-V08B-B); to this end, the UNCLE platform (UNcle-0469R, Unchained Labs) was           
used. 8.8 μL of CTC-445, CTC-445.2 and CTC-445.2d at 0.5 mg/mL, and hACE2 at 0.25               
mg/mL, were loaded in capillary cuvettes and fluorescence spectra (~300-400 nm) were            
measured for each sample while temperature was increased and decreased repeatedly.           
Temperature ramps were performed in the following order: 20 °C to 35 °C, 20 °C to 50 °C, 20                   
°C to 65°C, 20 °C to 80 °C, 20 °C to 95 °C, 20 °C to 80 °C, 20 °C to 65 °C, 20 °C to 50 °C and                             
20 °C to 35 °C. All samples were in PBS buffer pH 7.4. The barycentric mean was calculated for                   
each fluorescence spectrum using the UNCLE analysis program (Unchained Labs). 
Size-exclusion chromatography with multi-angle light scattering (SEC-MALS) 
SEC-MALS assays were performed using a 1260 infinity II LC HPLC system (Agilent             
Technologies) with a Superdex 75 10/300 size exclusion column (GE Healthcare), coupled to an              
inline static light scattering instrument (MiniDawn, Wyatt Technology) and differential          
refractive index (Optilab rEX, Wyatt Technology) and UV detection systems. Protein samples            
were prepared in a PBS buffer at concentrations ranging from 2 to 4 mg/mL and filtered with                 
0.22 µm syringe filters; 100 μL of the samples were injected and ran at a flow rate of 0.5                   
mL/min. Data were analyzed using the software ASTRA 7 (Wyatt Technologies). 
ELISA competition assays 
SARS-CoV2 S Protein RBD (Acro, Cat#EP-105) was coated at 0.5 µg/mL (100 uL/well) in              
flat, clear bottom, high binding polystyrene 96-well plate (Thermo, Cat#15041) overnight at 4°C.             
On the following day, each assay plate was washed 3X with 0.05% Tween-PBS and blocked               
with 2% BSA/0.05%Tween-PBS for 1-1.5 hours at 37°C. On the following day, 11-point             
four-fold serial dilutions of each test article were prepared starting at 2 µM (2X final). In                
addition, a dose response of biotin-hACE2 was prepared by performing a two-fold serial dilution              
starting at 0.174 µg/mL (2 nM). From the 0.174 µg/mL biotin-hACE2, a constant concentration              
of 0.07 µg/mL (0.8 nM, 2X final) was prepared to be used for inhibition by test articles. After                  
blocking, each assay plate was washed (3X) and each test article dilution was added to the plate                 
at 50 µL/well (single replicate well per concentration) followed by 50 µL/well of biotin-hACE2              
(~0.035 µg/ml, equivalent to a concentration of 0.4 nM). Incubation of test articles with 0.4 nM                
biotin-hACE2 was performed for 1 hour at 37°C. Afterwards, each assay plate was washed (3X),               
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followed by incubation of 0.1 µg/mL (100 µL/well) streptavidin-HRP for 1 hour at 37 °C. Lastly,                
each plate was washed (3X) before addition of 100 µl/well TMB (abCam, Cat#171524). TMB              
was incubated for 7-8 minutes and the reaction was stopped with the addition of 50 µL/well                
TMB Stop Solution (abCam, Cat# ab171529). Mean absorbance in each well was measured from              
4 spots at 450 nm for 5 different samples at each concentration. 
Biolayer interferometry 
Binding function of CTC-445 was analyzed by biolayer interferometry. Binding data were            
collected in an Octet RED96 (ForteBio) and processed using the instrument’s integrated software             
using a 1:1 binding model for CTC-445, CTC-445.2 and CTC-445.3, and 2:1 for CTC-445.2d,              
CTC-445.3d, and CTC-445.2t. SARS-CoV-2 Spike Protein (RBD domain only, his Tag, Sino            
Biological, Cat#40592-V08B-B) were immobilized to Anti-Penta-His sensors (HIS1K, ForteBio)         
at 2 μg/mL in binding buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05%                  
surfactant P20, 0.5% non-fat dry milk). After baseline measurement in the binding buffer alone,              
the binding kinetics were monitored by dipping the biosensors in wells containing defined             
concentrations of the designed protein (2.4-200 nM) (association) and then dipping the sensors             
back into baseline wells (dissociation).  
Expression and purification of SARS-CoV-2 S ectodomain 
Expression and purification of SARS-CoV-2 ectodomains were conducted as previously          
described ​(​55​)​. Briefly, constructs encoding the SARS-CoV-2 S ectodomain (residues 16-1206)           
with 6P stabilizing mutations ​(​56​)​, a mutated furin cleavage site between S1 and S2, and a                
C-terminal hexahistidine tag were used to express soluble SARS-CoV-2 S ectodomains.           
SARS-CoV-2 6P S trimers were purified from the supernatants of transiently-transfected           
Expi293F cells (Gibco) by nickel affinity and size-exclusion chromatography. Peak fractions           
were identified by SDS-PAGE, and fractions corresponding to S trimers were stored at 4˚C. 
Cryo-EM sample preparation, data collection, processing and refinement 
Purified CTC445.2 was incubated on ice for 30 min with SARS-CoV-2 S 6P trimer (1.1:1               
molar ratio CTC445.2 per S protomer) to a final complex concentration of 2.5 mg/mL. Cryo-EM               
sample grids were made as previously described ​(​55​)​. 
For cryo-EM data collection, 2,250 movies were collected using Serial EM ​(​57​) with             
beam-image shift over a 3 by 3 pattern of 1.2 µm holes with a single exposure per hole on a 200                     
kV Talos Artica (ThermoFisher). Movies were collected in super resolution mode on a K3 with a                
pixel size of 0.438 Å. Pre-processing was done in cryoSPARC ​(​58​) v2.15, including patch              
motion correction with binning by 2 and patch CTF estimation. Micrographs were screened by              
estimated CTF fit (≤ 6Å) and relative ice thickness (≤ 1.2), resulting in 1,610 images that were                 
used for particle picking via Blob picker. 658,188 particles were extracted and downsampled by              
4 (108 box size, 3.344 Å/pixel) and subjected to reference-free 2D classification. 2D class              
averages which displayed distinct views and secondary structural features were selected,           
resulting in 420,998 particles used to generate three ​ab initio ​volumes. The full set of particles                
(187,629) corresponding to the CTC445.2-S complex were re-extracted unbinned (432 box size,            
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0.869 Å/pixel), homogeneously refined, and underwent CTF refinement and aberration          
correction. 
The resulting volume was refined to an overall estimated resolution of 3.4Å (FSC=0.143),             
but flexibility and complex heterogeneity precluded analysis of the CTC445.2-RBD interface.           
Therefore, particles were further subjected to iterative rounds of 3D classification and            
homogeneous refinement. This procedure yielded four almost equally distributed classes with           
different CTC445.2 bound states, with overall estimated resolutions ranging from 3.8-4.2Å           
(FSC=0.143). To further improve features of the CTC445.2-RBD interface, complex states 3 and             
4 were grouped and used to generate a focused mask that removed CTC445.2 bound “up” RBDs.                
Local refinement that was focused on the CTC445.2 bound “partially-down” RBD resulted in an              
overall resolution of 4 Å, with improved features at the CTC445.2-RBD interface. 
Coordinates for the state 4 complex were generated by rigid-body docking individual            
chains from reference structures (PDB 6XKL and computationally-derived models of CTC445.2)           
into the final refined cryo-EM volumes using UCSF Chimera ​(​59​)​. Models were then refined              
using iterative rounds of real space refinement in Phenix ​(​60​) with rotameric and NCS restraints               
applied, followed by manual refinement in Coot ​(​61​) to correct geometry and ramachandran             
outliers. Validation of model coordinates was performed using MolProbity ​(​62​) with mean ADP             
B-factors of 175 and 180 Å​2​ for protein and ligands, respectively. 
Deep mutational scanning 
All positions in the CTC445.2 protein, and positions in the SARS-CoV-2 S protein RBD              
within 10Å of the ACE2 interface were mutated by PCR mutagenesis using custom primers              
(IDT, Coralville, IA) to introduce an NNK codon at each position of interest, as described               
previously ​(​63​)​. PCR products were purified using a QiaQuick gel extraction kit (Qiagen,             
Hilden, Germany), and 4 µg of each resulting site-saturation mutagenesis (SSM) library was             
transformed independently along with 1 µg of linearized pETcon3 vector into EBY100 yeast via              
electroporation with a final transformation efficiency of 1x10​6 transformants, as described           
previously ​(​64​)​. The resulting libraries were expressed by surface display. The RBD SSM library              
was sorted by FACS at varying concentrations of CTC-445.2 or hACE2 (656.1, 218.7, 72.9,              
24.3, 8.1, 2.7, 0.3, 0.1 nM, Sino Biological Cat#10108-H08H) and the CTC445.2 SSM library              
was sorted at varying concentrations of mFc tagged SARS-CoV-2 RBD (100, 50, 25, 12.5, 6.25,               
3.125, and 1.625 pM, Sino Biological Cat#40592-V05H), as described for the directed evolution             
experiment, with all cells showing binding fluorescence above the no-binder baseline collected            
for downstream analysis. In addition, for each pool, a nonbinding pool was collected             
representing all cells that showed expression in the absence of either CTC-445.2 or hACE2 or               
the SARS-CoV2 RBD, respectively. All sorted libraries, as well as an unselected library were              
processed to recover plasmid DNA, and were then amplified via two rounds of PCR followed by                
QiaQuick gel extraction using custom primers to add Illumina sequencing primer bind sites,             
barcodes, and flow cell adapters, as previously described ​(​65​)​. Prepared libraries were then sent              
for Illumina sequencing (GENEWIZ, South Plainfield, NJ), with a yield of between ~802k and              
~1440k reads per library. Enrichment was evaluated for mutations at the following positions in              
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the SARS-CoV-2 S protein RBD: 401, 402, 403, 404, 405, 406, 408, 409, 410, 416, 417, 418,                 
419, 420, 421, 422, 437, 439, 440, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453,                   
454, 455, 456, 457, 458, 459, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 482, 483,                   
484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502,                   
503, 504, 505, 506, 507, 508. Sequencing data was matched to the DNA sequence for the RBD                 
or CTC-445.2 without alignment (33 bases were trimmed from the 5’ end and 30 from the 3’                 
end); any sequences containing insertions or deletions were discarded. Sequencing data was            
filtered to remove bases with phred quality score Q<15. To ensure sufficient coverage to              
compute enrichment, only mutations with more than 10 counts in the expression-only dataset             
were analyzed. To determine enrichment, the number of occurrences in each dataset of each              
possible position and amino acid were first computed. Next, enrichment factors for all amino              
acid substitutions were determined. For each dataset, enrichment was calculated as the            
proportional counts for each dataset divided by the proportional counts for the expression-only             
dataset, giving 8 enrichment values for each position and amino acid in the RBD library               
corresponding to the 8 concentrations tested for both CTC-445.2 and ACE2, with 7 values in the                
CTC445.2 library for its 7 tested concentrations of RBD. The natural logarithm of the maximum               
enrichment of these values for ACE2, CTC-445.2, or the RBD was used as an estimate of the                 
effect of each amino acid substitution on binding. 
VSV-luc pseudovirus neutralization 
Neutralization activity was determined using a non-replicative VSV pseudovirus containing          
a firefly luciferase gene and expressing the spike protein from Wuhan-1 SARS-CoV-2 isolate             
(GenBank: QHD43416.1).  
Neutralization assays were performed with either SARS-CoV-2 / VSV-Luc (expressing the           
full ectodomain of the SARS-CoV-2 spike protein on the surface of the pseudovirus) or VSVg /                
VSV-Luc (expressing VSVg). Thirty thousand 293T-ACE2 cells were seeded the day before in             
white plates in the presence of hygromycin (100 μg/mL). The day of the neutralization assay, 25                
μL of media containing pseudovirus was mixed with 25 μL of serial dilutions of the test-item in a                  
different plate, and then incubated for 1 h at 37°C. Pseudovirus and test-item dilutions were               
performed in DMEM media containing 5% heat-inactivated fetal bovine serum (DMEM5). After            
the 60 minute incubation, the test-item / pseudovirus mixture was added to the 293T-ACE2 cells.               
Infection was allowed for twenty-four hours. Firefly luciferase activity was monitored at 24h             
using the Britelite reporter gene assay (Perkin Elmer). 
Test-items were evaluated in duplicate using serial 3-fold dilutions. Controls included cells            
infected with a VSV pseudovirus lacking spike protein (NoEnv / VSV-Luc), with pseudovirus             
carrying VSVg (VSVg / VSV-Luc), or uninfected cells (“mock-infected”). Pseudovirus-infected          
cells were incubated with test-item or vehicle alone (DMEM5). Some wells included cells             
challenged with pseudoviruses incubated with dilutions of plasma from a convalescent patient            
recovered from COVID-19 (COV+) or with a control plasma (COV-). Before collecting blood             
from COV+, this patient had been confirmed infected with SARS-CoV-2 by RT-PCR, and also              
for the presence of IgGs against SARS-CoV-2 Spike (S) evaluated with a lateral flow antibody               
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test. COV- plasma was derived from a PCR-negative and IgG-negative for S antibodies. 
Average RLU values in mock-infected cells were subtracted from all values           
(“mock-subtracted values”). The average RLU value of infected samples in the presence of             
vehicle was obtained. For each data point, once the mock was subtracted, the value was divided                
by the average value in infected cells in the presence of vehicle alone and then multiplied by 100                  
to obtain the percentage infectivity value normalized to samples with vehicle alone. The average              
percentage infectivity for each concentration together with the standard deviation of duplicates            
was obtained from duplicate values generated as shown in point 4. 
The 50% viral inhibitory concentration (EC​50​) was determined with GraphPad Prism. The            
EC​50 was defined as the concentration of test-item at which the relative luminescence units              
(RLUs) were reduced by 50% as compared with the values in cells infected with pseudovirus in                
the absence of test-item).  All measurements were carried out in 2 biological replicates. 
Viral infection assay of the SARS-CoV-2 virus in Vero E6 cells 
Vero E6 cells (ATCC #CRL-1586, ATCC, Manassas, VA) were maintained in Dulbecco’s            
Modified Eagle Medium (DMEM) supplemented with 4.5 g/L D-glucose, 100 mg/L sodium            
pyruvate, 10% FBS, 100,000 U/L penicillin–streptomycin and 25 mM HEPES. SARS-CoV-2           
virus (BetaCoV/Hong Kong/ VM20001061/2020), was isolated from the nasopharynx aspirate          
and throat swab a confirmed COVID-19 patient in Hong Kong at the end of January 2020                
(GISAID# EPI_ISL_412028) and was passaged 3 times in Vero E6 cells. All experiments using              
the SARS-CoV-2 isolate were performed at the core BSL3 facility, LKS Faculty of Medicine,              
The University of Hong Kong. The inhibitory effects of CTC-445.2 and CTC-445.2d were firstly              
evaluated with SARS-CoV-2 at the multiplicity of infection (MOI) of 1.0 or 0.01 TCID50/cell in               
96-well plates. Three-fold serially diluted CTC445.2 (final concentrations ranged from 30 µM to             
0.01 µM) and CTC445.2d (final concentrations range from 10 µM to 0.005 µM) were              
pre-incubated with diluted SARS-CoV-2 virus for 1 hour at 37°C and the mixture was added to                
Vero E6 and further incubated 1 hour at 37°C. The inoculum was removed and cells were                
overlaid with fresh infection media (DMEM supplemented with 4.5 g/L D-glucose, 100 mg/L             
sodium pyruvate, 2% FBS, 100,000 U/L Penicillin-Streptomycin, and 25 mM HEPES)           
containing matched concentrations of CTC-445.2 and CTC-445.2d. After 72 hours incubation at            
37°C, culture supernatants were collected to determine viral load (viral RNA copies/mL) using             
TaqMan™ Fast Virus 1-Step Master Mix as described ​(66)​. Four-parameter logistic regression            
(GraphPad Prism) was used to fit the dose-response curves and determined EC​50 of CTC-445.2              
and CTC-445.2d. To confirm the mechanism of inhibition, time-of-addition assay was used to             
evaluate the inhibitory effect of CTC-445.2 and CTC-445.2d. To test the effect of the, decoy               
proteins in blocking SARS-CoV-2 virus entry, 3-fold serially diluted CTC-445.2 and           
CTC-445.2d were pre-incubated with SARS-CoV-2 for 1 hour at 37°C and the mixture was              
added to Vero E6 cells and further incubated for 1 hour at 37°C. The inoculum was then                 
removed and the cells were washed in PBS three times before fresh infection media (without               
CTC-445.2 or CTC-445.2d) was added to the cells. To test the effect of the decoy protein in                 
blocking SARS-CoV-2 under multi-cycle replication, SARS-CoV-2 virus was allowed to          
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incubate with Vero E6 cells for 1 hour at 37°C; the inoculum was removed and the cells were                  
washed in PBS three times before infection media containing 3-fold serially diluted CTC-445.2             
and CTC-445.2d were added. Culture supernatants were collected at 72 hours post-infection to             
determine viral load (viral RNA copies/mL). Three biological replicates were performed.           
Dose-response data was fit to a three-parameter nonlinear fit using the scipy python module ​(67)​,               
with the upper bound of the curve fixed to the experimentally determined data points at               
concentration=0 µM.  
Viral infection assay of the NanoLuc SARS-CoV-2 virus in Calu-3 cells 
Calu-3 (ATCC HTB-55) from American Type Culture Collection (ATCC, Manassas, VA)           
was maintained in growth medium comprising OptiMEM with 20 mM HEPES, 10 mM             
GlutaMAX, 4% FBS, 10,000 IU/mL Penicillin, 10,000 µg/mL Streptomycin, and 10ng/mL           
Epidermal Growth Factor (EGF). Vero cells (USAMRIID) and icSARS-CoV-2-nLuc) (Isolate          
USA-WA1/2020) were generously provided by Dr. Ralph Baric Lab at University of North             
Carolina at Chapel Hill (Hou et al., Cell. 182, 1-18. 2020). icSARS-CoV-2-nLuc virus stock was               
propagated in Vero cells and stored at -80 °C. Calu3 cells are seeded in white 96-well                
flat-bottomed tissue culture plates. All viral infections were performed in the biosafety level 3              
facility at the University of Washington. Three-fold serial dilution of test compound CTC-445.2             
(final concentration ranging from 20 µM to 0.01 µM) and CTC-445.2d (final concentration             
ranging from 10 µM to 0.0046 µM) were added to corresponding wells during virus infection at                
MOI of 1.0; three independent experiments were performed in duplicate. After virus adsorption             
at 37℃ for 1 h, inoculum was removed and replaced with fresh growth media containing the                
same compound concentration to maintain the treatment throughout the entire infection course.            
To estimate the antiviral effects of test compounds, icSARS-CoV-2-nLuc virus replication was            
measured by adding Nano-Glo Endurazine Live Cell substrate to each well, and nanoLuc             
readings of the same well were taken at 24, 48, and 72 hours post-infection. NanoLuc reads                
were normalized to the untreated wells, and the inhibitory effects of the compounds on virus               
replication were analyzed by non-linear regression curve fit algorithm by using GraphPad Prism. 
Human proteome binding specificity 
CTC445.2d at 1 µg/mL (=30 nM) chemically labeled with Alexa-647 was used for the              
protein-protein interaction assay. A HuProt​TM array (CDI Laboratories, Baltimore, MD) with           
barcodes containing 21,218 proteins and protein isoforms (including S protein RBD) was            
incubated with the protein sample for 1 hour. After probing,the arrays were washed and images               
were taken for data collection. CDI software was used to quantify the binding profile of each                
individual sample to specific proteins on the array based on Z Scores. Z scores were computed                
using the average Z score of the duplicate spots of a given protein (each protein is printed in                  
duplicate on a HuProt​TM ​array). The Z score of each spot on a given array is calculated according                  
to the formula Z = [F635–F635(avg)] / F635(std), where F635 is the average foreground signal               
intensity of 2 replicate spots of a given protein in the detection channel (635 nm); B635 is the                  
average background signal intensity of 2 replicate spots of a given protein in the detection               
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channel; and F635(avg) and F635(std) are the average and standard deviation of the F635 values               
of all spots on the array, respectively. S score is the difference of the Z scores of a given protein                    
and the one ranked after it. If the S score of the top hit is > 3, the test protein is considered as                       
highly specific against that hit. 
Cytotoxicity assay 
Cytotoxicity of the test compounds in treated Vero-E6 or Calu-3 cells was tested using the               
Cell Counting Kit-8 (CCK-8) assay (Abcam). Cells were seeded in 96-well flat-bottom tissue             
culture treated plates. Four-fold serial dilutions of test compound CTC-445.2 and CTC-445.2d in             
fresh infection medium (final concentrations ranging from 60 µM to 3.7 nM for CTC-445.2 and               
50 µM to 3 nM for CTC-445.2d, respectively) were added onto corresponding Vero E6 cells.               
Three-fold serial dilutions of the test compounds of CTC-445.2 (final concentration ranging from             
20 µM to 0.01 µM) or CTC-445.2d (final concentration ranging from 10 µM to 0.0046 µM) in                 
Calu-3 cell growth media were added onto the cells. Cells were then incubated at 37℃, 5% CO​2                  
for 2 days. 10 µL CCK-8 reagent was added to each well, and the absorbance was measured at                  
460 nm.  
Single-dose pharmacokinetics of the de novo decoys 
Eight week old female Balb/c mice (DOB 28-Apr-2020; Charles River Strain Code 028)             
were anesthetized with isoflurane and a single 100 µg (30 µL of 3.37 mg/mL) dose of                
low-endotoxin (<5.0 EU/mg) CTC-445.2d was delivered intranasally. Mice were euthanized at           
indicated time points and whole blood and tissue (lungs, trachea or nasal turbinates) isolated.              
Five biological replicates were performed for plasma, lungs, and trachea, and three for nasal              
turbinates. Whole blood was centrifuged, and plasma was separated from cells by pipetting into a               
separate tube before freezing. Tissue lysates were prepared through mechanical disruption of            
tissue using Precellys tissue homogenizer (Bertin), followed by lysis with T-PER tissue lysis             
buffer (ThermoFisher) containing protease/phosphatase inhibitor cocktail (ThermoFisher).       
Lysates were cleared by centrifugation and were frozen for analysis. A standard 96-well MSD              
(L15XA) plate was pre-coated with 50 µL/of 0.5 µg/mL SARS-CoV-2 S Protein RBD tagless              
(Sino, 40592-VNAH) overnight at 4 ℃ and sealed. Dilution of capture reagent was prepared in               
PBS. On the following day, the assay plate was washed (6X) with 0.05% Tween-PBS and               
blocked with 150 µL/well MSD Blocker A (5% protein-PBS solution) for a minimum of 2 hours                
at RT. Plate shaking was performed for all incubation periods. During blocking incubation, a              
standard curve was prepared by performing a 4-fold serial dilution of CTC-445.2d in either              
untreated lung lysate or untreated plasma at 10,000 ng/mL. Prior to addition to the assay plate,                
each sample and standard was diluted 5-fold (MRD = 5) into assay dilution buffer (0.5% MSD                
Blocker A). In addition, samples were diluted 10-fold in separate wells. After blocking, an assay               
plate was washed (6X) and 50 µL/well of each sample or standard dilution was added. Assay                
plate was incubated for additional 1 hour at RT with plate shaking followed by washing (6X).                
For detection, a 1-step detection method was used. With 1-step detection, rabbit anti-His mAb              
(RevMab, 31-1048-00) and SULFOTAG goat anti-rabbit IgG (H+L) pAb (MSD, R32AB) were            
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pre-mixed at 1 µg/mL each for 1 hour prior to addition to assay plate at 50 µL/well. After the last                    
wash, 150 µL/well of MSD Gold Read Buffer was added and luminescence measured on the               
MSD Quickplex SQ120. Luminescence was converted to concentration based on a standard            
curve. All procedures were done in accordance with the National Research Council’s Guide for              
the Care and Use of Laboratory Animals and The Animal Welfare Act and were reviewed and                
approved by The Bloodworks Northwest Research Institute Institutional Animal Care and Use            
Committee (IACUC, project ID 5360-01). 
Multi-dose mouse toxicity of CTC-445.2d 
A 100 µg flat dose (30 µL of 3.33 mg/mL stock) of low-endotoxin (<2.0 Eu/mg),               
His-tagged CTC-445.2d (~5 mg/kg for 20 g mouse) was intranasally administered to 18 female              
CD-1 mice (DOB 12-May-2020, age ~13 weeks; Charles River Strain Code 022) daily for 14               
days. In addition, a control group of 5 untreated mice were dosed similarly with PBS. On days 1,                  
2, 4, 8, 11 and 14, body weight of surviving mice was recorded and three CTC-445.2d-treated                
mice were sacrificed for lung examination and CTC-445.2d quantification in lung lysate (data             
not shown). All procedures were done in accordance with the National Research Council’s Guide              
for the Care and Use of Laboratory Animals and The Animal Welfare Act and were reviewed                
and approved by The Bloodworks Northwest Research Institute Institutional Animal Care and            
Use Committee (IACUC, project ID 5360-06). 
Syrian hamster ​in vivo​ model for SARS-CoV-2 infection 
Syrian hamsters (Mesocricetus auratus, males, 3 to 4 months of age), were purchased from             
Charles River (Wilmington, MA, USA). Hamsters were single housed in Tecnipast Greenline            
IVC unit – GR900 cages purchased from Tecniplast (West Chester, PA) containing Anderson             
Bed O’ Cobs 1/8 inch animal bedding (The Andersons INC., Maumee, OH) as well as Nylabones                
(Lab Supply, Fort Worth, TX) for enrichment. Hamsters were provided with Lab Diet Rodent              
Chow (Lab Diet, St. Louis, MO) and fresh water ad libitum. The University of Georgia               
Institutional Animal Care and Use Committee approved all hamster experiments (A2020           
04-024-Y1-A3; 27-May-2020), which were conducted in accordance with the National Research           
Council’s Guide for the Care and Use of Laboratory Animals, The Animal Welfare Act, and the                
CDC/NIH’s Biosafety in Microbiological and Biomedical Laboratories guide. 
The hamsters were anesthetized using isoflurane and i.n. treated with 100 µL of             
CTC-445.2d at a concentration of 5.6 mg/mL, or with vehicle (PBS) for the control group.               
Hamsters were challenged, 12-hours later, with 100 µL of i.n. administered SARS-CoV-2            
(Washington/1/2020) at 5e+5 plaque forming units (PFU) per hamster. Clinical signs for this             
study included lethargy, rough coat, moderate dyspnea, hunched back, and weight loss of             
10-20%. Severe clinical signs requiring immediate euthanasia included sever dyspnea (open           
mouth gasping), lack of response to external stimuli, and weight loss >20%. All challenged              
hamsters were weighed daily up to day 7. Any hamster that exceeded 20% weight loss from its                 
original weight or displayed severe clinical symptoms was humanely euthanized. The scoring            
system for assessing clinical symptoms is as follows, signs of: lethargy (1 point), rough coat (1                
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point), moderate dyspnea (2 points), hunched back (1 point), and body weight loss 10-20% (1               
point). Hamsters that accumulated a clinical score of 3 or higher were euthanized. All procedures               
were performed in accordance with the Guide for the Care and Use of Laboratory Animals,               
Animal Welfare Act, and Biosafety in Microbiological Laboratories. 
ACE2 solution enzymatic activity assay 
Inhibition of ACE2 enzymatic activity was performed using the ACE2 Inhibitor Screening            
Kit (Promocell Heidelberg, Germany). 50 µL of ACE2 enzyme solution was added to each well               
of a 96-well white walled plate (Corning, New York). Duplicate test samples were diluted to 20                
µM in the provided assay buffer for the highest concentration, with an 8 point 1 to 4 serial                  
dilution. DX600 was used as the ACE2 inhibitor positive control. 10 µL of diluted samples were                
added to the ACE2 enzyme solution and incubated for 15 min at room temperature. 40 µL of                 
ACE2 substrate mix was then added to each well. After 15 min, fluorescence was measured in an                 
Infinite M1000 plate reader (Tecan Männedorf, Switzerland) with 320 nm excitation and 420             
emission filters. Fluorescence values were normalized using negative controls.  
ACE2 in vitro cellular enzymatic activity assessment 
Vero E6 cells (ATCC #CRL-1586, ATCC, Manassas, VA) were transduced with an ACE2             
Lentivirus (BPS Bioscience San Diego, CA) to increase ACE2 surface expression. ACE2-Vero            
cells were seeded in a 96-well white walled plate at 10,000 cells per well in 100 µL of DMEM                   
with 10% FBS and 1% pen-strep and rested overnight. Test compounds CTC-445.2,            
CTC-445.2d, and positive control DX600 were serially diluted in a 96-well polypropylene plate.             
Concentration of test compounds started at 8 µM with an 8 point 1 to 4 serial dilution. Culture                  
media was aspirated and cells were incubated with 50 µL of diluted test compounds for 1 hour at                  
37 °C. Mca-APK(Dnp) ACE2 substrate was diluted to 50 µM. 50 µL diluted ACE2 substrate               
was added to each well and incubated at 37°C. Data were collected for 10 wells (DX600), 5                 
wells (CTC-445.2) or 6 wells (CTC-445.2d). 20 hours after adding ACE2 substrate, fluorescence             
was read at 320 nm excitation and 400 nm emission on the Infinite M1000 plate reader (Tecan                 
Männedorf, Switzerland). 
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Fig. S1. Target mechanism of inhibition of SARS-CoV-2 by the de novo designed ACE2 decoys.​  SARS-CoV-2                
(and SARS-CoV) gains entry into cells by first binding to the ACE2 receptor on the surface of human cells via the                     
spike protein (left). The spike protein binds to the de novo designed ACE2 decoys using the same binding interface                   
as natural ACE2, effectively making decoys functionally resilient to mutation. The SARS-CoV-2 spike protein binds to                
the decoys instead of native ACE2, sequestering the virus and preventing viral entry into cells while keeping native                  
ACE2 function intact (right).  
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Fig. S2. Three dimensional structures of ACE2 in-complex with SARS-CoV-1 and SARS-CoV-2 RBD. A)              
Comparison of ACE2 models used to identify motifs for designed proteins. H1 (orange), H2 (green), EE3 (blue), and                  
H4 (red) are the motifs that interact with the RBD of SARS-CoV-1 (pink, left), a SARS-CoV-1+SARS-CoV-2 chimera                 
(light green, middle) and SARS-CoV-2 (light blue, right). Computational designs were created against one of these                
structures, but evaluated against the S protein RBD from all three RBDs. ​B) Structural motifs involved in binding of                   
spike protein to ACE2 and their interactions with SARS-CoV-2 spike protein. H1 and H2 were present in all designs,                   
and EE3 was present in the majority of designs. To simplify the design process of the de novo decoys, we did not                      
incorporate the fourth binding motif (H4) in our design strategy because we predicted it to have a minor contribution                   
to binding. 
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Fig. S3. Yeast display characterization of CTC-445 binding to SARS-CoV-2 RBD and SARS-CoV-1 RBD. ​A)               
Yeast-display titration assay to estimate the binding ​K​D of CTC-445 for SARS-CoV-2 RBD. Yeast displaying CTC-445                
were incubated with increasing concentrations of SARS-CoV-2 RBD (0, 1, 3, 9, 27, 81 and 243 nM, see methods).                   
On the right, steady state plot to reveal a ​K​D of 6 nM. ​B) Yeast-display competition assay to estimate the IC​50 @                      
hACE2[0.4nM] of hACE2 to compete binding of CTC-445 to SARS-CoV-2 RBD. Yeast displaying CTC-445 were incubated                
with SARS-CoV-2 9 nM and increasing concentrations of hACE2 (0, 1, 3, 9, 27, 81, 243 and 729 nM, see methods).                     
On the right, steady state plot to reveal an IC​50 @ hACE2[0.4nM] = 49 nM. ​C) Screen for binding of CTC-445 to SARS-CoV-1                       
RBD. Yeast displaying CTC-445 were incubated with SARS-CoV-1 RBD at 200 nM (see methods), with no                
observable binding at this concentration. 
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Fig. S4: Binding kinetics and thermal stability of hACE2. ​Binding kinetics (left) of hACE2 to immobilized                
SARS-CoV-2 RBD (300 nM to 4.7 nM); data were globally fit using a 1:1 binding model. Thermal-induced unfolding                  
(center) measured by circular dichroism at 208 nm was fit using a two-states equation; a T​m value of 52.5 ± 0.5 °C                      
was calculated. The inset shows far UV spectra at 20 °C, 99 °C and 20 °C after heating and cooling the sample.                      
Thermal-recovery assay (right); BCM signal does not return to the initial value after repeated cycles of heating and                  
cooling which indicates poor reversibility.  
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Fig. S5: Chemical and thermal stability of the de novo protein decoys. A) Chemical denaturation of CTC-445,                 
CTC-445.2 and CTC-445.2d by incubation with guanidine hydrochloride (0-6 M). Calculated values of ΔG​ND​, ΔG​NI and                
ΔG​ID were -9.8 ± 0.8, -2.7 ± 1.1 and -7.1 ± 0.7 kcal mol​-1 for CTC-445, -14.6 ± 2.0, -5.0 ± 2.8 and -9.6 ± 2.0 kcal mol​-1                            
for CTC-445.2, and -19.0 ± 1.7, -4.4 ± 2.3 and -14.6 ± 1.6 kcal mol​-1 for CTC-445.2d; ​B) Thermal recovery of                     
CTC-445, CTC-445.2 and CTC-445.2d. Similar values of BCM were observed before and after repeated cycles of                
heating and cooling for the three proteins.  
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Fig. S6. Sequence alignment for the directed evolution of CTC-445 using error-prone PCR and yeast display                
FACS. ​Error Prone PCR was performed on the gene coding for CTC-445 to identify mutations that improve its                  
stability and affinity to SARS-CoV-2. A DNA library of 2x10​6 CTC-445 variants was generated and transformed into                 
yeast for yeast display. Six rounds of yeast sorting were performed, with increasingly stringent binding conditions. For                 
every round of cell sorting, the CTC-445 library was first treated with a mixture of trypsin and chymotrypsin (see                   
methods), washed, and then allowed to bind to SARS-CoV-2 RBD at concentrations of: 200 nM for round 1, 10 nM                    
for round 2, 1 nM for round 3, 100 pM for round 4, 10 pM for round 5 and 1 pM for round 6 (see methods). The top                            
5% binders for every round were sorted using fluorescence-activated cell sorting (FACS) and selected cells were                
plated on selective SDCAA plates for sequencing. Cartoon representations of the sequences are shown here with H1                 
in orange, H2 in green, EE3 in blue and supporting motifs in magenta. CTC-445 is shown on the top and positions                     
where mutations were found are indicated with the residue letter. Ten sequences were picked in the first round of                   
sorting, highlighted with a dashed box. Mutations found in round 1 in combination with rational design led to the                   
CTC-445 second generation variants in Table S2, which includes CTC-445.2. CTC-445.2 is five mutations away from                
CTC-445 (M6L, E86G, F116L, R124S and R126L, highlighted in red). The more stringent rounds of sorting further                 
confirmed mutations M6L, F116L and R126L and revealed new mutations (e.g. A2V and A155V) that are located in                  
the core of the design and were shown to further improve stability (see Fig. S21).  
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Fig. S7. Potency of CTC-445 variants vs. their molecular weights. IC​50 @ hACE2[0.4nM] values for CTC-445 variants for                  
binding to SARS-CoV-2 S/RBD were measured by ELISA in the presence of 0.4 nM biotinylated soluble hACE2.                 
hACE2 bound to RBD was quantified by treatment with streptavidin-HRP and measurement of absorbance at 450                
nm.   
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Fig. S8. Mass spectrometry and SEC-MALS analysis of de novo designed decoys CTC-445, CTC-445.2 and               
CTC-445.2d using a Superdex 75 Increase 10/300 GL size-exclusion column. ​Mass spectrometry and peptide              
mapping coverage for CTC-445.2 (upper left) and CTC-445.2d (lower left). ​Light scattering signal (gray, dashed) and                
280nm UV absorption signal (black, continuous). Chromatogram traces are normalized to the peak with the highest                
intensity for clarity. Flow rate 0.5 mL/min, injection volume: 100 mL. After isolation of the monomeric CTC-445 (upper                  
right) and CTC-445.2 (center right) chromatograms shown a small population of high molecular weight aggregates               
and oligomeric species with high light scattering; while CTC445.2d (lower right) shows evidence of a minuscule                
population of dimeric oligomer with small light scattering. In all cases chromatograms exhibit excellent              
monomer-oligomer separation and the light scattering signal exhibits high signal-to-noise ratio. The calculated             
molecular weights are shown for the fractions of the highest UV signal. For CTC445.2 and CTC445.2d the monomer                  
MW values exhibit high homogeneity and the Mw/Mn ratio was 1.0 which indicates the proteins are monodisperse.  
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Fig. S9. Sequence and structural similarity of CTC-445.2 to natural proteins. ​A) Sequential (lineal) structural               
alignments, using TMalign, take into account the order of the secondary structure elements in the polypeptide chain.                 
Each datapoint represents a structural alignment of CTC-445.2 to a single PDB from a non-redundant structure                
database of 14,433 PDB chains (see methods). Sequence identity is computed based on the structurally aligned                
residues. Although CTC-445.2 mimics the ACE2 binding surface, it does not align well in lineal structure or sequence                  
to any protein in the database, including ACE2. ​B) MICAN in rewiring/reverse mode, which allows inverse direction of                  
secondary structures, alternative alignments, and non-sequential alignments. The highest sequence identity observed            
for CTC-445.2 is with ACE2 (33.7% for aligned residues), which is approximately the fraction of solvent-exposed                
ACE2 residues from the starting RBD-binding motifs that were preserved (35%). ​C) Comparison of the SARS-CoV-2                
RBD (beige) binding interface with the computational model of CTC-445.2 and the hACE2 interface (gray; PDB:                
6M17). CTC-445.2 residues from each binding motif are colored: H1 (orange), H2 (green) and EE3 (blue). ACE2                 
residue numbers are shown in parentheses. Right, comparison of the SARS-CoV-2 binding interface surface of               
CTC-445.2 (top) and hACE2 (bottom). CTC-445.2 is designed to present the same binding interface as the one that                  
SARS-CoV-2 targets in hACE2, down to the level of individual amino acid interactions. 
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Fig. S10. Characterization of CTC-445.2t. CTC-445.2t is a tri-valent avid version of CTC-445 with further improved                
binding affinity and high thermodynamic stability. ​A) Design model of CTC-445.2t, a serial repeat of three CTC-445.2                 
molecules separated by two 16-residue linkers (sequence -GGGSGGSGSGGSGGGS-). ​B) Thermal denaturation of            
CTC-445.2t, followed by circular dichroism at 208 nm (20 °C to 99 °C at 2 °C/min). A three-state fit revealed two                     
melting temperatures, T​m,1 ​= 71 ± 0.5 °C and T​m,2 ​= 90 ± 1.6 °C. The inset shows the far UV spectra at 20 °C (purple),                          
after heating to 99 °C (brown) and after cooling to 20 °C again (green), to show complete recovery of the                    
ellipticity-spectra. ​C) Chemical denaturation using guanidine hydrochloride (0-6 M). Calculated values of ΔG​ND​, ΔG​NI​,              
and ΔG​ID were -26.5 ± 5, 3.7 ± 6 and -22.8 ± 4 kcal mol​-1​. ​D) Thermal recovery was observed after cycles of heating                        
and cooling, as CTC-445.2t went back to similar BCM values after each cycle. ​E) Binding kinetics to immobilized                  
SARS-CoV-2 RBD measured using biolayer interferometry (CTC-445.2t concentrations of 0.5, 0.9, 1.9, 3.8, 7.5, 15               
and 30 nM). Results were fit using a 2:1 binding model to reveal a ​K​D = 0.27 ± 0.07 nM. ​F) Binding kinetics to                        
immobilized SARS-CoV-1 RBD measured using biolayer interferometry (CTC-445.2t concentrations of 78.1, 156.2,            
312.5, 625, 1250, 2500 and 5000 nM). Results were fit using a 2:1 binding model to reveal a ​K​D = 212 ± 54 nM. ​G)                         
Potency of CTC-445.2t to outcompete binding of SARS-CoV-2 to ACE2, measured by ELISA with a constant                
concentration of 0.4 nM ACE2 and a range of CTC-445.2t concentrations from 0.001 to 1000 nM, revealed an IC​50 @                    
hACE2[0.4nM] ​= 0.11 nM.  
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Rank Protein Fluorescence Z Score S Score 
1 SARS-CoV-2 RBD 65535 88.6 27.6 
2 QDPR 45252 61.0 19.3 
3 KCNAB1 31053.5 41.7 10.6 
4 KCNAB1 23248.5 31.0 1.0 
5 CLEC10A 22530 30.1 7.3 
6 TMEM120A 17165 22.8 5.4 
7 CRYZ 13218.5 17.4 2.7 
8 ZADH2 11256.5 14.7 0.0 
9 KCNAB2 11221.5 14.7 0.0 
10 F2 11214.5 14.6 2.9 
Fig. S11. Binding specificity of CTC445.2d assessed using a comprehensive human proteome binding assay.              
A) The binding profile of CTC445.2d (concentration of 1 µg/mL (30 nM), chemically labeled with Alexa-647, see                 
methods) to a complete array of 21,218 (17,164 unique) human proteins (HuProt human proteome array, CDI Labs,                 
see methods). Binding to each individual protein is quantified by a Z score based on the mean fluorescence of each                    
spot in the array. If the S score (Z score difference) of the top hit is > 3.0 from the next hit, the test protein is                          
considered highly specific against the top hit. The table shows all hits with Z score > 10. CTC445.2d demonstrates                   
specific binding to the SARS-CoV-2 RBD, with a Fluorescence value of 65,535 translating to the highest Z Score of                   
88.6. The S score to the next highest binding gene, QDPR, is 27.6, demonstrating highly specific binding to the                   
intended target RBD of SARS-CoV-2. ​B) The binding of CTC-445.2d to immobilized SARS-CoV-2 RBD-his,              
QDPR-his and CLEC10A-his was tested by biolayer interferometry. No binding to QDPR and CLEC10A was detected                
at any tested concentrations of CTC-445.2d (10 µM, 5 µM and 1 µM).  
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Fig. S12. cryoEM data processing and validation of the CTC-445.2-S complex. A) Representative micrograph              
and ​B) 2D class averages. ​C) 3D classification and refinement workflow. After homogenous refinement of particles                
corresponding to the CTC-445.2-S trimer ab initio model, particles were classified into four distinct classes and                
subjected to iterative rounds of CTF refinement, homogenous refinement, and local refinement. ​D) Final fourier shell                
correlation (FSC) plots calculated from half-maps of masked data for each state. Blue line represents FSC=0.143. ​E)                 
Representative density from focused refinement of CTC-445.2-RBD interface. While the overall map resolution was              
4.1Å (FSC=0.143), discernable side chain features allowed for accurate modeling of CTC-445.2 (blue).  
26 
 
 
 
 
Fig. S13. Assessment of cryoEM map quality. A-D​) Euler angle distribution plots, and ​E-H) local resolution                
estimations for reconstructions corresponding to States 1-4. The local resolution estimate for the focused              
classification and local refinement of CTC-445.2 bound to a “partially-down” RBD is highlighted. ​I-K) Representative               
density from SARS-CoV-2 S trimer regions of the State 4 map in which coordinates were modeled (map contour level                   
= 3​σ). 
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Fig. S14. Deep mutational scanning of the SARS-CoV-2 RBD binding interface, effect on binding (by yeast                
display) of CTC-445.2 and hACE2 at 8 different concentrations. ​A) The upper left plot shows the correlation                 
between the observed counts of each mutant in the initially constructed site-saturation mutagenesis library (SSM) and                
the observed counts in the library after sorting for successful yeast display (see methods). The remaining 8 plots                  
show the enrichments of RBD mutations after selection for binding to CTC-445.2 vs. ACE2. Each data point is a                   
single amino acid mutation at a given position of the RBD. Yeast display FACS for binding were performed at                   
concentrations of: 656.1, 218.7, 72.9, 24.3, 8.1, 2.7, 0.3, 0.1 nM of CTC-445.2 or hACE2 (see methods). The dotted                   
line is the trace of a theoretical perfect correlation. The SSM library was designed to include all the 19 possible                    
natural-amino acid mutations for the 75 residues composing the RBD binding interface with hACE2 and it’s second                 
layer of interaction. At the lowest concentration (100 pM), five outlier mutations were found to increase RBD binding                  
affinity to hACE2 but decrease binding affinity to CTC445.2. ​B) Enrichments averaged across all 8 selection                
conditions as in Fig. 4B and also averaged per residue. For all the scatter plots, the coloration indicates the                   
secondary structure(s) interacting with the amino acid position (same color scheme in A and B). 
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Fig. S15. In vitro neutralization of VSV-Luc pseudovirus in ACE2-transfected HEK293T cells. ​CTC-445.2 and              
CTC-445.2d neutralized VSV pseudovirus expressing SARS-CoV-2 (top). We observed no inhibition of pseudovirus             
infection in HEK293T cells expressing VSVg with CTC-445.2 and CTC-445.2d (center), demonstrating specificity for              
the RBD of SARS-CoV-2, with no discernable loss of HEK293 cell viability (bottom). All data points are shown (n=2). 
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Fig. S16. ACE2 functional activity in the presence of CTC-445.2 and CTC-445.2d. ​ACE2 functional activity was                
measured by enzymatic release of a free fluorophore fromMca-APK(DNP) substrate in solution (left) and in Vero E6                 
cells (right). The de novo decoys did not affect ACE2 function. DX600 was used as positive control (see methods).   
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Fig. S17. Inhibition of SARS-CoV-2 (cytopathic effect) in Vero E6 cells. ​Observed qualitative cytopathic effect of                
SARS-CoV-2 infection of Vero E6 cells at 72 hours post infection, where CTC-445.2 or CTC-445.2d is present                 
throughout infection, post-infection only and pre-infection only.  
 
31 
 
 
 
 
Fig. S18: In vitro neutralization of live BetaCoV/Hong Kong/VM20001061/2020 SARS-CoV-2 virus in Vero E6              
cells. The cells were incubated with CTC-445.2d at MOI 0.01 (left) and CTC-445.2 at MOI=0.01 (center) and                 
MOI=1.0 (right) throughout infection (i.e. before infection, during infection and post infection) (orange/blue),             
post-infection only (black) and pre-infection only (gray). SARS-CoV-2 RNA copy numbers were determined by              
quantitative real-time RT-PCR. All assays were performed in triplicate unless otherwise noted, and all data points are                 
shown. 
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Fig. S19. In vivo mouse pharmacokinetics of intranasally administered CTC-445.2d. Concentration of fully             
functional CTC-445.2d (i.e. capable of binding to the SARS-CoV-2 RBD, see methods) found in homogenized lungs,                
nasal turbinates, plasma, and trachea of Balb/c mice after a single 100 µg dose, measured at indicated times after                   
dosing (n=5 mice for plasma, lung, and trachea, n=3 mice for nasal turbinates). The dotted gray line indicates the                   
quantification limit.  
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Fig. S20: Kinetics of binding for CTC-445.2 to SARS-CoV-2 RBD mutants. Five RBD mutants were immobilized                
via Anti-Penta-His sensors, and CTC-445.2 was titrated in solution. Data was globally fit to a 1:1 model for each RBD                    
mutant. The inset shows the steady state plot.  
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Fig. S21. CTC-445.3d, a further optimized CTC-445.2d variant. Stability, thermal kinetics, binding and in vitro               
neutralization. CTC-445.3d is a further stability-enhanced variant. Similarly to CTC-445.2d, CTC-445.3d is a bivalent              
molecule that contains three additional (i.e. compared to CTC-445.2) amino acid substitutions (A2V, I41L and R142L)                
in each of the (two) functional domains. ​A) Thermal denaturation of CTC445.3d was followed by circular dichroism at                  
208 nm, from 20 °C to 99 °C at 2°C/min. A two-state fit revealed a Tm of 89 ± 2 °C, which is 17 °C higher than the Tm                             
of CTC-445.2d. The inset shows the far UV spectra at 20 °C (purple), 99 °C (brown) and 20 °C (green), to show                      
recovery after heating and cooling. ​B) Heating cycles (20, 35, 50, 65, 80, 95 °C, and vice versa down) revealed that                     
CTC-445.3d only loses its secondary structure at the highest heating cycle (95 °C) and goes back to similar BCM                   
values after each temperature cycle. ​C) Binding kinetics of CTC-445.3d to immobilized SARS-CoV-2 RBD (300 nM to                 
4.7 nM) using octet. Results were fit using a 2:1 binding model to reveal a ​K​D​= 1 nM, k​on​= 4.2 x 10​5 M​-1 s​-1​, and k​off​=                          
1.4 x 10​-2 s​-1​. ​D) In vitro neutralization of the live BetaCoV/HongKong/VM20001061/2020 SARS-CoV-2 virus by               
CTC-445.3d in Vero E6 cells, with the protein present throughout the infection and using two different multiplicity of                  
infections (MOIs) (0.01 and 1.0), three replicates each. Determination of the SARS-CoV-2 RNA copy numbers               
revealed an EC50 of 3.1 nM at MOI 0.01 and an EC50 of 38 nM at MOI 1.0. 
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Table S1. De novo designed decoys, sequences and kinetics of binding to the SARS-CoV-2 S protein RBD.                 
The RBD (either for SARS-CoV-1 or SARS-CoV-2) was immobilized to the OCTET sensor (Streptavidin SA for                
SARS-CoV-1 and Anti-Penta-HIS HIS1K SARS-CoV2, ForteBio) and incubated with varying concentrations of ACE2             
decoys. Binding kinetics were monitored by dipping the biosensors in wells containing defined concentrations of the                
de novo decoys (5 nM, 19 nM, 38 nM, 75 nM, 150 nM and 300 nM for binding to SARS-CoV-2 and 39 nM, 78 nM,                         
156 nM, 312 nM, 625 nM, 1250 nM and 2500 nM for binding to SARS-CoV-1) and then dipping the sensors back into                      
baseline wells (dissociation). Both, steady state and fitted kinetic values are shown. 
Decoy   RBD k​on (M​-1​ s​-1​) 
k​off 
(s​-1​) 
K​D​ kinetics 
(nM) 
    ​K​D​ steady-state 
(nM) 
hACE2 SARS-CoV-1 6.8 x 10​4 1.0 x 10​-3 14 43 
SARS-CoV-2 8.6 x 10​4 4 x 10​-4 4.7 31 
CTC-445 SAEIDMGKGDFREIRASEDAREAAEALAEAARAMKEALEIIREIAEKLRDSSRASEAAKRIAKAIRKAADAIAEAAKIAARAAKDEDAA
RNAENAARKAKEFAEEQAKLADMYAEFAKNGDKSRVREQLKTFADKAFHEMEDRFYQAALAVFEAAEAAAG 
SARS-CoV-1 ~ 4.5 x 10​4 ~2.5 x 10​-1 ~ 5.5 x 10​4   ND 
SARS-CoV-2 8.6 x 10​4  5.5 x 10​-2  646  357 
CTC-445.2 SAEIDLGKGDFREIRASEDAREAAEALAEAARAMKEALEIIREIAEKLRDSSRASEAAKRIAKAIRKAADAIAEAAKIAARAAKDGDAAR
NAENAARKAKEFAEEQAKLADMYAELAKNGDKSSVLEQLKTFADKAFHEMEDRFYQAALAVFEAAEAAAGGSGWGSG 
SARS-CoV-1 1.0 x 10​5 3.9 x 10​-1 3.8 x 10​3 ~ 7 x 10​3 
SARS-CoV-2 3.9 x 10​5 1.2 x 10​-2 30 21 
SARS-CoV-2_N354D 5.0 x 10​5 1.5 x 10​-2  30 22 
SARS-CoV-2_N354D_D364Y 7.4 x 10​5 1.5 x 10​-2  20 16 
SARS-CoV-2_V367F 5.9 x 10​5 1.3 x 10​-2  22 17 
SARS-CoV-2_R408I 5.1 x 10​5  1.7 x 10​-2  33 26 
SARS-CoV-2_W436R 6.8 x 10​5  8.7 x 10​-2  13 8 
CTC-445.2d SAEIDLGKGDFREIRASEDAREAAEALAEAARAMKEALEIIREIAEKLRDSSRASEAAKRIAKAIRKAADAIAEAAKIAARAAKDGDAAR
NAENAARKAKEFAEEQAKLADMYAELAKNGDKSSVLEQLKTFADKAFHEMEDRFYQAALAVFEAAEAAAGGGGSGGSGSGGSG
GGSPGSAEIDLGKGDFREIRASEDAREAAEALAEAARAMKEALEIIREIAEKLRDSSRASEAAKRIAKAIRKAADAIAEAAKIAARAAK
DGDAARNAENAARKAKEFAEEQAKLADMYAELAKNGDKSSVLEQLKTFADKAFHEMEDRFYQAALAVFEAAEAAAGGSGWGS 
SARS-CoV-1 3.7 x 10​5  4.7 x 10​-1 1.2 x 10​3 587 
SARS-CoV-2 3.0 x 10​5  ≤ 2.0 x 10​-3  ≤ 7.0 3.5 
CTC-445.2t SAEIDLGKGDFREIRASEDAREAAEALAEAARAMKEALEIIREIAEKLRDSSRASEAAKRIAKAIRKAADAIAEAAKIAARAAKDGDAAR
NAENAARKAKEFAEEQAKLADMYAELAKNGDKSSVLEQLKTFADKAFHEMEDRFYQAALAVFEAAEAAAGGGGSGGSGSGGSG
GGSPGSAEIDLGKGDFREIRASEDAREAAEALAEAARAMKEALEIIREIAEKLRDSSRASEAAKRIAKAIRKAADAIAEAAKIAARAAK
DGDAARNAENAARKAKEFAEEQAKLADMYAELAKNGDKSSVLEQLKTFADKAFHEMEDRFYQAALAVFEAAEAAAGGGGSGGSG
SGGSGGGSPGSAEIDLGKGDFREIRASEDAREAAEALAEAARAMKEALEIIREIAEKLRDSSRASEAAKRIAKAIRKAADAIAEAAKIA
ARAAKDGDAARNAENAARKAKEFAEEQAKLADMYAELAKNGDKSSVLEQLKTFADKAFHEMEDRFYQAALAVFEAAEAAAGGSG
WGSG 
SARS-CoV-1 5.4 x 10​5 0.1 188 212 
SARS-CoV-2 1.4 x 10​6 ≤ 9.1 x 10​-5 ≤ 0.065 0.27 
CTC-445.3d SVEIDLGKGDFREIRASEDAREAAEALAEAARAMKEALEILREIAEKLRDSSRASEAAKRIAKAIRKAADAIAEAAKIAARAAKDGDAA
RNAENAARKAKEFAEEQAKLADMYAELAKNGDKSSVLEQLKTFADKAFHEMEDLFYQAALAVFEAAEAAAGGGGSGGSGSGGSG
GGSPGSVEIDLGKGDFREIRASEDAREAAEALAEAARAMKEALEILREIAEKLRDSSRASEAAKRIAKAIRKAADAIAEAAKIAARAAK
DGDAARNAENAARKAKEFAEEQAKLADMYAELAKNGDKSSVLEQLKTFADKAFHEMEDLFYQAALAVFEAAEAAAGGSGWGSG 
SARS-CoV-1 ND ND ND ND 
SARS-CoV-2 4.2 x 10​5 1.4 x 10​-2 3 1 
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Table S2. Characterization of the expression, solubility and binding of CTC-445 variants. ​CTC-445 variants              
were generated by rationally combining mutations discovered by directed evolution and characterized. ​Columns             
indicate the qualitative expression level (0-5), solubility (0-5), and binding affinity (0-5). Propensity for aggregation               
indicates whether large molecular weight aggregates or oligomers were present during size exclusion             
chromatography, and the fraction of non-monomeric protein is measured by comparing peak areas for monomeric               
and oligomeric species by analytical size exclusion chromatography. 
Design ID Description 
Expression 
level 
(Cat. 0-3) 
Solubility 
(Cat. 0-3) 
Binding 
strength (Cat. 
0-5) 
Propensity for 
aggregation 
SEC 
monomeric 
fraction 
(%) 
CTC-00445 CTC-445      
CTC-00613 CTC-445_S1P 2 1 1   
CTC-00614 CTC-445_M6L 3 2 3   
CTC-00615 CTC-445_F152W 3 2 1   
CTC-00616 CTC-445_F11Y 3 2 1   
CTC-00617 CTC-445_F11K 2 3 2   
CTC-00618 CTC-445_R42S 2 1 1   
CTC-00619 CTC-445_E46S 2 2 1   
CTC-00620 CTC-445_A88N 3 2 N.D.   
CTC-00621 CTC-445_F116N 2 3 1   
CTC-00622 CTC-445_R124S 3 3 2   
CTC-00623 CTC-445_F137V 3 3 N.D.   
CTC-00624 CTC-445_R143L 2 3 3   
CTC-00625 
CTC-445_S1P_F11Y_R42S_E46S_A88N
_F116N_R124S_F137V_R143L 3 3 N.D.   
CTC-00626 
CTC-445_S1P_M6L_F11Y_R42S_E46S_
A88N_F116N_R124S_F137V_R143L_F1
52W 2 3 0.5   
CTC-00627 
CTC-445_S1P_F11K_R42S_E46S_A88N
_F116N_R124S_F137V_R143L 2 3 N.D.   
CTC-00628 
CTC-445_S1P_M6L_F11K_R42S_E46S_
A88N_F116N_R124S_F137V_R143L_F1
52W 2 3 2   
CTC-00629 CTC-445_E74C 3 2 1   
CTC-00630 CTC-445_K63C 2 1 Not screened   
CTC-00631 CTC-445_F11C 2 1 N.D.   
CTC-00632 CTC-445_E74C_F11Y 2 3 1 0 17% 
CTC-00633 CTC-445_K63C_F11Y 2 1 1 1  
CTC-00634 
CTC-445_E74C_S1P_M6L_F11Y_R42S_
E46S_A88N_F116N_R124S_F137V_R14
3L_F152W 2 3 N.D. 0 82% 
CTC-00635 
CTC-445_K63C_S1P_M6L_F11Y_R42S_
E46S_A88N_F116N_R124S_F137V_R14
3L_F152W 2 3 N.D. 0 86% 
CTC-00636 
CTC-445_S1P_M6L_F11C_R42S_E46S_
A88N_F116N_R124S_F137V_R143L_F1
52W 0 1 N.D. 1  
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CTC-00637 {PG}.CTC-445_M6L_R126L 1.5 2 4 0 97% 
CTC-00638 {PG}.CTC-445_F116L_R124S 0.5 3 Not screened 1  
CTC-00639 
{PG}.CTC-445_M6L_F116L_R124S_R12
6L 2 2 4.5 0 92% 
CTC-00640 
(CTC-445.2) 
{PG}.CTC-445_M6L_E86G_F116L_R124
S_R126L 2 3 4.5 0 99% 
CTC-00641 
{PG}.CTC-445_A2V_E3V_M6L_I61V_K63
R_A73V_K84T_E86G_A92V_A95E_K100
Q_F116L_R124S_R126L_A136T_R143S 2 3 3.5 0 95% 
CTC-00642 {PG}.CTC-445_M6L_F11C_R126L 3 2 4.5 1  
CTC-00643 {PG}.CTC-445_M6L_K63C_R126L 3 2 4.5 0 59% 
CTC-00644 {PG}.CTC-445_M6L_E74C_R126L 3 2 4.5 0 89% 
CTC-00645 {PG}.CTC-445_F11C_F116L_R124S 3 2 Not screened   
CTC-00646 {PG}.CTC-445_K63C_F116L_R124S 3 2 3.5 1  
CTC-00647 {PG}.CTC-445_E74C_F116L_R124S 3 2 3 1  
CTC-00648 
{PG}.CTC-445_M6L_F11C_F116L_R124
S_R126L 2 3 5 0 85% 
CTC-00649 
{PG}.CTC-445_M6L_K63C_F116L_R124
S_R126L 2 3 4.5 0 87% 
CTC-00650 
{PG}.CTC-445_M6L_E74C_F116L_R124
S_R126L 0.5 3 4.5 0 90% 
CTC-00651 
{PG}.CTC-445_A2V_E3V_M6L_F11C_I61
V_K63R_A73V_K84T_E86G_A92V_A95E
_K100Q_F116L_R124S_R126L_A136T_
R143S 2 3 4 0 97% 
CTC-00652 
{PG}.CTC-445_A2V_E3V_M6L_I61V_K63
R_K63C_A73V_K84T_E86G_A92V_A95E
_K100Q_F116L_R124S_R126L_A136T_
R143S 2 3 4 0 89% 
CTC-00653 
{PG}.CTC-445_A2V_E3V_M6L_I61V_K63
R_A73V_E74C_K84T_E86G_A92V_A95E
_K100Q_F116L_R124S_R126L_A136T_
R143S 2 3 4 0 86% 
CTC-00654 
(CTC-445.2d) 
{PG}.CTC-445_M6L_E86G_F116L_R124
S_R126L_X2 2 3 5   
CTC-00655 
{PG}.CTC-445_A2V_E3V_M6L_I61V_K63
R_A73V_K84T_E86G_A92V_A95E_K100
Q_F116L_R124S_R126L_A136T_R143S
_X2 2 3 5   
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Table S3. SARS-CoV-2 neutralization by CTC-445.2 and CTC-445.2d in a time-of-addition experiment.            
*Recombinant protein was present before (pre-incubating with virus for 1h), during (1 h) and post SARS-CoV-2                
infection (72 h) in Vero E6 cells. ​#​Recombinant protein was added post SARS-CoV-2 infection. ​@​Recombinant protein                
was pre-incubated with virus for 1 h and the virus-recombinant protein mix was added to Vero E6 cells and incubated                    
for 1 h. The cells were washed with PBS after infection and overlaid with media without recombinant protein. 
Proteins 
Inhibitory concentration at 
MOI= 1.0 (µM)  
Inhibitory concentration at 
MOI= 0.01 (µM) 
CPE 
formation 
Reduction in 
viral RNA 
copy 
numbers 
(EC​50​)  
CPE 
formation 
Reduction in 
viral RNA 
copy 
numbers 
(EC​50​) 
Experiment 1: Inhibitory effect throughout the course of infection* 
CTC-445.2 10 1.807  2.31 0.753 
CTC-445.2d 0.37 0.0235  0.01 <0.005 
Experiment 2: Post-infection inhibitory effect​# 
CTC-445.2 30 ~10  10 2.947 
CTC-445.2d 3.33 0.2369  0.12 0.0139 
Experiment 3: Pre-infection inhibitory effect​@ 
CTC-445.2 >30 >30  ~30 ~29.33 
CTC-445.2d >10 ~3.903  3.33 2.688 
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Table S4. CryoEM data collection, refinement, and validation statistics. 
 
 CTC-445.2 
SARS-CoV-2 S 
6P 
(state 4) 
CTC-445.2 
SARS-CoV-2 S 
6P 
(state 1) 
CTC-445.2 
SARS-CoV-2 S 
6P 
(state 2) 
CTC-445.2 
SARS-CoV-2 S 
6P 
(state 3) 
PDB     
EMD     
     
Microscope Talos Arctica Talos Arctica Talos Arctica Talos Arctica 
Camera Gatan K3 Summit Gatan K3 Summit Gatan K3 Summit Gatan K3 Summit 
Magnification 45,000x 45,000x 45,000x 45,000x 
Voltage (kV) 200 200 200 200 
Recording mode counting counting counting counting 
Dose rate (e​-​/pixel/s) 15.6 15.6 15.6 15.6 
Electron dose (e​-​/Å​2​) 60 60 60 60 
Defocus range (µm) 0.8 - 2.0 0.8 - 2.0 0.8 - 2.0 0.8 - 2.0 
Pixel size (Å) 0.869 0.869 0.869 0.869 
Micrographs collected 2,250 2,250 2,250 2,250 
Micrographs used 1,610 1,610 1,610 1,610 
Extracted particles 420,998 420,998 420,998 420,998 
Total refined particles 187,629 187,629 187,629 187,629 
Particles in final volume 26,038 39,795 47,013 37,342 
     
Symmetry imposed C1 C1 C1 C1 
Nominal Resolution (Å)     
FSC 0.5 (masked/unmasked) 4.5/8.8 4.4/8.6 4.3/9.4 6.6/9.8 
FSC 0.143 (masked/unmasked) 4.1/6.5 3.8/7.5 3.8/6.8 4.2/7.8 
Map sharpening B-factor (Å​2​) -70.9 -73.2 -68.9 -100.3 
     
Refinement and Validation     
Model-to-map resolution (FSC 0.143/0.5) 4.0/4.3    
Number of atoms     
Protein 26,857    
Ligand 518    
MapCC (global/local) 0.79/0.81    
R.m.s. deviations     
Bond lengths (Å) 0.01    
Bond angles (˚) 0.7    
MolProbity score 2.8    
CaBLAM outliers (%) 2.79    
Clashscore (all atom) 13.6    
Poor rotamers (%) 0.1    
Ramachandran plot     
Favored (%) 93.8    
Allowed (%) 6.2    
Disallowed (%) 0    
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Table S5. Mean clinical scores for the Syrian hamsters data presented in Fig. 5C: ​A) SARS-CoV-2 challenged                 
and CTC-445.2d treated, as well as the control groups: B) SARS-CoV-2 challenged and PBS treated, and C)                 
unchallenged and untreated. The scoring system for assessing clinical symptoms is: lethargy (1 point), rough coat (1                 
point), moderate dyspnea (2 points), hunched back (1 point), and body weight loss 10-20% (1 point). Hamsters that                  
accumulated a clinical score of 3 or higher were euthanized. 
 
Day A) Challenged, 
CTC-445.2d-treated 
 B) Challenged, 
PBS-treated 
C) Unchallenged, 
untreated 
0 0 0 0 
1 0 0 0 
2 1 1 0 
3 1 1 0 
4 1 1 0 
5 1 1 0 
6 1 1.3 0 
7 1 3 0 
10 0.25 - 0 
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Appendix A. Python/PyRosetta code to generate multiple initial perturbations for mobile           
secondary structure elements​.  
 
####################################################################################################################### 
################################################START################################################################## 
####################################################################################################################### 
 
import argparse 
import os 
import numpy as np 
import uuid 
import pyrosetta 
 
def _gaussian(): 
return pyrosetta.rosetta.numeric.random.rg().gaussian() 
 
def extract_subpose(pose_in, selector): 
pose = pose_in.clone() 
 
not_selector=pyrosetta.rosetta.core.select.residue_selector.NotResidueSelector() 
not_selector.set_residue_selector(selector) 
subset = not_selector.apply(pose) 
 
ranges = pyrosetta.rosetta.core.select.residue_selector.ResidueRanges(subset) 
intervals = [] 
for rang in ranges: 
 intervals.append((rang.start(), rang.stop())) 
 
for start, stop in reversed(intervals): 
 pose.delete_residue_range_slow(start, stop) 
 
return pose 
 
def extract_chains(pose_in, chains_str): 
''' 
Convenience function to extract a list of chains from a pose 
''' 
selector = pyrosetta.rosetta.core.select.residue_selector.ChainSelector(chains_str) 
return extract_subpose(pose_in, selector) 
 
def split_pose(inPose, selectors): 
inPoseByChain=pyrosetta.rosetta.utility.vector1_core_pose_Pose() 
for selector in selectors: 
 sel_pose=extract_subpose(inPose, selector) 
 inPoseByChain.append(sel_pose) 
return inPoseByChain 
 
def join_poses(poses): 
assert len(poses) >= 1 
joined = None 
for pose in poses: 
 if joined is None: 
 joined = pose.clone() 
 else: 
 offset = joined.size() 
 joined.append_pose_by_jump(pose, 1) 
 # copy pdb info 
 for seqpos in range(1, pose.size()+1): 
 joined_seqpos = seqpos + offset 
 joined.pdb_info().chain(joined_seqpos, pose.pdb_info().chain(seqpos)) 
 joined.pdb_info().number(joined_seqpos, pose.pdb_info().number(seqpos)) 
 for label in pose.pdb_info().get_reslabels(seqpos): 
 joined.pdb_info().add_reslabel(joined_seqpos, label) 
joined.pdb_info().obsolete(False) 
return joined 
 
def rodrigues_rotation(a, 
 angle, 
 verbose=False): 
#from math import cos, sin, acos, asin, sqrt, pi, radians, degrees 
"use Rodrigues' rotation formula to get rotation matrix" 
a = np.array(a, dtype=float) 
a /= np.sqrt(np.inner(a, a)) # make unit vector 
omega = np.array([[   0., -a[2],  a[1]], 
 [ a[2], 0., -a[0]], 
 [-a[1],  a[0], 0.]], dtype=float) 
rm = (np.identity(3) + omega * np.sin(angle) 
 + np.dot(omega, omega) * (1 - np.cos(angle))) 
return rm 
 
class PackstatSimpleMetric(pyrosetta.rosetta.core.simple_metrics.RealMetric): 
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def __init__(self, nrepeats=5): 
 super(PackstatSimpleMetric, self).__init__() 
 self.nrepeats = nrepeats 
 
def name(self): 
 return self.__class__.__name__ 
 
def metric(self): 
 return 'packstat' 
 
def calculate(self, pose): 
 result_array=[] 
 for i in range(self.nrepeats): 
 result_array.append(pyrosetta.rosetta.core.scoring.packstat.compute_packing_score(pose)) 
 value = np.average(result_array) 
 return value 
 
class CentroidScoreSimpleMetric(pyrosetta.rosetta.core.simple_metrics.RealMetric): 
def __init__(self, weights=['cen_std.wts', 'interchain_cen.wts'], min_score=-99999): 
 super(CentroidScoreSimpleMetric, self).__init__() 
 self.min_score = min_score 
 self.sfxn = pyrosetta.rosetta.core.scoring.ScoreFunction() 
 for filename in weights: 
 self.sfxn.add_weights_from_file(filename) 
 self.sfxn.set_weight(pyrosetta.rosetta.core.scoring.ScoreType.atom_pair_constraint, 1.0) 
 
def name(self): 
 return self.__class__.__name__ 
 
def metric(self): 
 return 'centroid_score' 
 
def calculate(self, in_pose): 
 return self.sfxn(in_pose) 
 
class ClashCheckFilter(pyrosetta.rosetta.protocols.filters.Filter): 
def __init__(self, global_context_pose, 
 pick_mode=pyrosetta.rosetta.core.pose.PoseCoordPickMode_N_CA_C_CB, 
 radius=2.0): 
 self.global_context_pose = global_context_pose 
 self.pick_mode = pick_mode 
 self.radius = radius 
 self.global_context_pose_hash = pyrosetta.rosetta.core.pose.xyzStripeHashPose(self.global_context_pose, 
 self.pick_mode, self.radius) 
 
def clash_map_to_str(self, pose, clash_map): 
 newmap = {} 
 for rsd1, rsd2 in clash_map.items(): 
 pdb_info = pose.pdb_info() 
 r1 = '{}{}'.format(pdb_info.number(rsd1), pdb_info.chain(rsd1)) 
 pdb_info = self.global_context_pose.pdb_info() 
 r2 = '{}{}'.format(pdb_info.number(rsd2), pdb_info.chain(rsd2)) 
 newmap[r1] = r2 
 assert len(newmap) == len(clash_map) 
 return newmap 
 
def apply(self, pose): 
 # Extract balls 
 target_balls = pyrosetta.rosetta.utility.vector1_numeric_geometry_hashing_Ball() 
 pyrosetta.rosetta.core.pose.xyzStripeHashPose.extract_pose_balls(pose, 
 target_balls, 
 self.pick_mode) 
 
 # Get clash map 
 target_clash_map = pyrosetta.rosetta.std.map_unsigned_long_unsigned_long() 
 self.global_context_pose_hash.clash_check_residue_pairs(target_balls, 
 target_clash_map) 
 
 if len(target_clash_map) > 0: 
 return False 
 
 return True 
 
class RandomRoller(pyrosetta.rosetta.protocols.moves.Mover): 
def __init__(self, fixed_residue_selector, movable_residue_selectors, 
 distance_step, angle_step): 
 super(RandomRoller, self).__init__() 
 self.fixed_residue_selector = fixed_residue_selector 
 self.movable_residue_selectors = movable_residue_selectors 
 self.angle_step = angle_step 
 self.distance_step = distance_step 
 
def get_name(self): 
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 return self.__class__.__name__ 
 
def apply(self, pose): 
 movable_residue_sets, coord_sets, coms = self.generate_cached_data(pose) 
 for ix, mset in enumerate(movable_residue_sets): 
 #Calculate translation 
 tVec = np.zeros((3, ), dtype=float) 
 for iaxis in range(3): 
 tVec[iaxis] = _gaussian()*self.distance_step 
 
 #Calculate rotation 
 angle = _gaussian()*self.angle_step 
 rMat1 = rodrigues_rotation([pyrosetta.rosetta.numeric.random.gaussian(), 
 pyrosetta.rosetta.numeric.random.gaussian(), 
 pyrosetta.rosetta.numeric.random.gaussian()], 
 np.radians(angle)) 
 
 #Apply -T,R,+T 
 coor_array = coord_sets[ix] - coms[ix] 
 coor_array = np.dot(coor_array, rMat1) 
 coor_array += coms[ix] 
 coor_array += tVec 
 
 #Apply_coordinates_to_pose 
 tmp_cntr = 0 #It is easier just to keep a counter 
 for ires in mset: 
 rsd = pose.residue(ires) 
 for jatom in range(1, rsd.natoms()+1): 
 tmp_xyz = pyrosetta.rosetta.numeric.xyzVector_double_t(coor_array[tmp_cntr][0], 
 coor_array[tmp_cntr][1], 
 coor_array[tmp_cntr][2]) 
 pose.set_xyz(pyrosetta.rosetta.core.id.AtomID(jatom, ires), tmp_xyz) 
 tmp_cntr += 1 
 
def get_coordinates(self, pose, residues): 
 coords = [] 
 for seqpos in residues: 
 rsd = pose.residue(seqpos) 
 for atom_ix in range(1, rsd.natoms()+1): 
 xyz = pose.residue(seqpos).xyz(atom_ix) 
 coords.append([xyz[0], xyz[1], xyz[2]]) 
 return np.array(coords) 
 
def generate_cached_data(self, pose): 
 fixed_residue_subset = self.fixed_residue_selector.apply(pose) 
 fixed_residues = pyrosetta.rosetta.core.select.residue_selector.ResidueVector(fixed_residue_subset) 
 
 movable_residue_sets = [] 
 for sel in self.movable_residue_selectors: 
 movable_residue_subset = sel.apply(pose) 
 movable_residues = pyrosetta.rosetta.core.select.residue_selector.ResidueVector(movable_residue_subset) 
 movable_residue_sets.append(movable_residues) 
 
 # check for duplicate assignments 
 residue_set = set(fixed_residues) 
 for mset in movable_residue_sets: 
 for m in mset: 
 if m in residue_set: 
 raise Exception('Residue {} is present in more than one Rockpack residue selection'.format(m)) 
 residue_set.add(m) 
 for seqpos in range(1, pose.size()+1): 
 if seqpos not in residue_set: 
 raise Exception('Residue {} is not present in any Rockpack residue selection'.format(m)) 
 
 # find coordinates 
 coord_sets = [self.get_coordinates(pose, mset) for mset in movable_residue_sets] 
 coms = [np.mean(x, axis=0) for x in coord_sets] 
 return movable_residue_sets, coord_sets, coms 
 
class MonteCarlo(pyrosetta.rosetta.protocols.moves.Mover): 
def __init__(self, mover, metric, unique_run_id, 
 out_file_dir='.', 
 filters=[], 
 reporting_frequency=100, 
 num_perturbations=1000, 
 num_trajectories=1, 
 ): 
 self.mover = mover 
 self.metric = metric 
 self.filters = filters 
 self.reporting_frequency = reporting_frequency 
 self.num_perturbations = num_perturbations 
 self.num_trajectories = num_trajectories 
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 self.unique_run_id = unique_run_id 
 self.out_file_dir = out_file_dir 
 
def score(self, pose): 
 return self.metric.calculate(pose) 
 
def check_filters(self, pose): 
 for f in self.filters: 
 if not f.apply(pose): 
 return False 
 return True 
 
def run(self, pose): 
 ipose_start = pose 
 results = [] 
 for trajectory_id in range(self.num_trajectories): 
 ipose = self.run_trajectory(ipose_start, trajectory_id) 
 results.append((self.score(ipose), ipose)) 
 if not self.check_filters(ipose): 
 continue 
 
 if len(results) == 0: 
 raise Exception('ERROR: No trajectories produced any poses that passed the filters.') 
 
 results.sort() 
 return results[0][1] 
 
def write_pdb(self, pose, traj, pert): 
 pdb_file = '{}_rockpack_trajectory{:03d}_iteration{:06d}.pdb'.format(self.unique_run_id, traj, pert) 
 pdb_path = os.path.join(self.out_file_dir, 'debug', pdb_file) 
 pose.dump_pdb(pdb_path) 
 
def run_trajectory(self, ipose, traj_id): 
 mover = self.mover 
 metric = self.metric 
 
 best_score = metric.calculate(ipose) 
 best_pose = ipose.clone() 
 if debug: 
 self.write_pdb(best_pose, traj_id, 0) 
 for icounter in range(1, self.num_perturbations+1): 
 test_pose = ipose.clone() 
 mover.apply(test_pose) 
 test_score = metric.calculate(test_pose) 
  
 if icounter%self.reporting_frequency == 0: 
 print("\n\nWorking on scoring RockPerturbation %d"%icounter) 
 print("Best score", best_score, ipose) 
 
 if test_score < best_score: 
 if self.check_filters(test_pose): 
 if debug: 
 print('Found better score: {}, {}, {}'.format(icounter, best_score, test_score)) 
 self.write_pdb(test_pose, traj_id, icounter) 
 best_pose = test_pose 
 best_score = test_score 
 
 if debug: 
 self.write_pdb(best_pose, traj_id, self.num_perturbations+1) 
 return best_pose 
 
class CentroidRocker(MonteCarlo): 
def __init__(self, fixed_residue_selector, **kwargs): 
 super(CentroidRocker, self).__init__(**kwargs) 
 self.fixed_residue_selector = fixed_residue_selector 
 
def switch_to_centroid_mode(self, pose): 
 switch_to_centroid = pyrosetta.SwitchResidueTypeSetMover('centroid') 
 switch_to_centroid.apply(pose) 
 
def switch_to_fullatom_mode(self, pose): 
 switchToFA = pyrosetta.SwitchResidueTypeSetMover("fa_standard") 
 switchToFA.apply(pose) 
 
def constrain_atom_pairs(self, pose): 
 pairs = self._get_atom_pairs(pose) 
 func = pyrosetta.rosetta.core.scoring.constraints.BoundFunc(5.5, 9999, 0.1, 'CA-CA') 
 for iatom, jatom in pairs: 
 cst = pyrosetta.rosetta.core.scoring.constraints.AtomPairConstraint( 
 iatom, 
 jatom, 
 func) 
 pose.add_constraint(cst) 
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def apply(self, pose): 
 # Switch over to centroid mode 
 self.switch_to_centroid_mode(pose) 
   
 # Constrain atom pairs 
 self.constrain_atom_pairs(pose) 
 
 newpose = self.run(pose) 
 
 # Switch back to full atom mode 
 self.switch_to_fullatom_mode(newpose) 
 pose.assign(newpose) 
 
def _get_atom_pairs(self, pose): 
 fixed_residue_subset = self.fixed_residue_selector.apply(pose) 
 pairs = [] 
 for ires in pose.residues: 
 ## ires must be a rock pack chain 
 if fixed_residue_subset[ires.seqpos()]: 
 continue 
 
 iatom_index = ires.atom_index('CA') 
 iatom = pyrosetta.rosetta.core.id.AtomID(iatom_index, ires.seqpos()) 
 
 for jres in pose.residues: 
 ## jres must be a different chain 
 if jres.chain() == ires.chain(): 
 continue 
 
 jatom_index = jres.atom_index('CA') 
 jatom = pyrosetta.rosetta.core.id.AtomID(jatom_index, jres.seqpos()) 
 
 pairs.append((iatom, jatom)) 
 return pairs 
 
def pack_pose_generic(in_pose, 
 packaas=["A","L","I","V","F"], 
 scorefxn=None): 
packstatfilter=pyrosetta.rosetta.protocols.simple_filters.PackStatFilter() 
pack_task={} 
for ires in range(1,in_pose.total_residue()+1): 
 pack_task[ires]=packaas 
packed_pose=pack_rotamers_fast(in_pose=in_pose, 
 pack_task=pack_task, 
 pack_scorefxn=scorefxn) 
return packed_pose 
 
def pack_rotamers_fast(in_pose, 
 pack_task={}, 
 pack_scorefxn=None 
 ): 
test_pose = in_pose.clone() 
pack_scorefxn(test_pose) 
task = pyrosetta.standard_packer_task( test_pose ) 
for ipos in range(1,in_pose.total_residue()+1): 
 raa_bool = pyrosetta.rosetta.utility.vector1_bool(20) 
 for jndx in range( 20 ): 
 raa_bool[jndx+1]=False 
 if ipos in pack_task: 
 for jaa in pack_task[ipos]: 
 mutant_aa = pyrosetta.rosetta.core.chemical.aa_from_oneletter_code( jaa ) 
 raa_bool[int(mutant_aa)]=True 
 task.nonconst_residue_task( ipos 
 ).restrict_absent_canonical_aas( raa_bool ) 
  
#Pack 
pyrosetta.rosetta.core.pack.pack_rotamers(test_pose, 
 pack_scorefxn, 
 task) 
return test_pose 
 
def msd_bb_2_poses(pose1, 
 init_res1, 
 end_res1, 
 pose2, 
 init_res2, 
 end_res2): 
numRes=(end_res1-init_res1+1) 
coorA=np.zeros(((4*numRes),3), float) 
coorB=np.zeros(((4*numRes),3), float) 
  
counter=0 
47 
 
 
 
for res in range (init_res1, (end_res1+1)): 
 for dim in range(0,3): 
 coorA[counter,dim]=(pose1.residue(res).xyz("CA")[dim]) 
 counter+=1 
 for dim in range(0,3): 
 coorA[counter,dim]=(pose1.residue(res).xyz("C")[dim]) 
 counter+=1 
 for dim in range(0,3): 
 coorA[counter,dim]=(pose1.residue(res).xyz("O")[dim]) 
 counter+=1 
 for dim in range(0,3): 
 coorA[counter,dim]=(pose1.residue(res).xyz("N")[dim]) 
 counter+=1 
 
counter=0 
for res in range (init_res2, (end_res2+1)): 
 for dim in range(0,3): 
 coorB[counter,dim]=(pose2.residue(res).xyz("CA")[dim]) 
 counter+=1 
 for dim in range(0,3): 
 coorB[counter,dim]=(pose2.residue(res).xyz("C")[dim]) 
 counter+=1 
 for dim in range(0,3): 
 coorB[counter,dim]=(pose2.residue(res).xyz("O")[dim]) 
 counter+=1 
 for dim in range(0,3): 
 coorB[counter,dim]=(pose2.residue(res).xyz("N")[dim]) 
 counter+=1 
   
msdVal=0.0 
for i in range(len(coorA)): 
 tmpVal_buff= np.linalg.norm(coorA[i] - coorB[i]) 
 msdVal+=(tmpVal_buff*tmpVal_buff) 
msdVal=msdVal/len(coorA) 
msdVal=np.sqrt(msdVal) 
  
return msdVal 
 
class RockPackRMSDFilter(pyrosetta.rosetta.protocols.filters.Filter): 
def __init__(self, reference_pose, residue_selectors, max_rmsd): 
 super(RockPackRMSDFilter, self).__init__() 
 self.residue_selectors = residue_selectors 
 self.reference_pose = reference_pose.clone() 
 self.reference_pose_by_chain = None 
 self.max_rmsd = max_rmsd 
 
def apply(self, pose): 
 if self.reference_pose_by_chain is None: 
 self.reference_pose_by_chain = split_pose(self.reference_pose, self.residue_selectors) 
 
 tmp_test_ipose_by_chain = split_pose(pose, self.residue_selectors) 
 assert len(self.reference_pose_by_chain) == len(tmp_test_ipose_by_chain) 
 
 for kndx, (reference_pose, chain_pose) in enumerate(zip(self.reference_pose_by_chain, tmp_test_ipose_by_chain)): 
 assert reference_pose.size() == chain_pose.size() 
 tmp_this_msd_to_starting_point=msd_bb_2_poses( 
 reference_pose, 1, reference_pose.size(), 
 chain_pose, 1, chain_pose.size()) 
 self.last_msd_to_reference_pose = tmp_this_msd_to_starting_point 
 
 if tmp_this_msd_to_starting_point>self.max_rmsd: 
 return False 
 return True   
 
class RockPackMover(pyrosetta.rosetta.protocols.moves.Mover): 
def __init__(self, packaas=['V', 'I', 'L'], scorefxn=None): 
 super(RockPackMover, self).__init__() 
 if scorefxn is None: 
 self.scorefxn = pyrosetta.get_score_function() 
 else: 
 self.scorefxn = scorefxn 
 self.packaas = packaas 
 
def apply(self, in_pose): 
 pack_task={} 
 for ires in  range(1,in_pose.total_residue()+1): 
 pack_task[ires]=self.packaas 
 self.pack_rotamers_fast(in_pose=in_pose, pack_task=pack_task) 
 
def pack_rotamers_fast(self, in_pose, pack_task): 
 self.scorefxn(in_pose) 
 
 # Create task 
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 task = pyrosetta.standard_packer_task(in_pose) 
 for ipos in range(1, in_pose.total_residue()+1): 
 raa_bool = pyrosetta.rosetta.utility.vector1_bool(20) 
 for jndx in range( 20 ): 
 raa_bool[jndx+1]=False 
 if ipos in pack_task: 
 for jaa in pack_task[ipos]: 
 mutant_aa = pyrosetta.rosetta.core.chemical.aa_from_oneletter_code( jaa ) 
 raa_bool[int(mutant_aa)]=True 
 task.nonconst_residue_task(ipos).restrict_absent_canonical_aas(raa_bool) 
   
 # Pack 
 pyrosetta.rosetta.core.pack.pack_rotamers(in_pose, self.scorefxn, task) 
 
class CompoundMover(pyrosetta.rosetta.protocols.moves.Mover): 
def __init__(self, movers): 
 super(CompoundMover, self).__init__() 
 self.movers = movers 
 
def apply(self, pose): 
 for m in self.movers: 
 m.apply(pose) 
  
def rmsd_and_rosettaRotations_2_np_arrays(crds1, 
 crds2): 
 """Returns RMSD between 2 sets of [nx3] numpy array""" 
 COM1 = np.sum(crds1,axis=0) / crds1.shape[0] 
 COM2 = np.sum(crds2,axis=0) / crds2.shape[0] 
 crds1-=COM1 
 crds2-=COM2 
 n_vec = np.shape(crds1)[0] 
 correlation_matrix = np.dot(np.transpose(crds1), crds2) 
 v, s, w_tr = np.linalg.svd(correlation_matrix) 
 is_reflection = (np.linalg.det(v) * np.linalg.det(w_tr)) < 0.0 
 if is_reflection: 
 s[-1] = - s[-1] 
 v[:,-1] = -v[:,-1] 
 E0 = sum(sum(crds1 * crds1)) + sum(sum(crds2 * crds2)) 
 rmsd_sq = (E0 - 2.0*sum(s)) / float(n_vec) 
 rmsd_sq = max([rmsd_sq, 0.0]) 
 rMtx=np.dot(v, w_tr) 
 tVec=COM1-(np.dot(COM2, np.linalg.inv(rMtx))) 
 rMtx_xyzM=pyrosetta.rosetta.numeric.xyzMatrix_double_t() 
 rMtx_xyzM.xx=rMtx[0,0] 
 rMtx_xyzM.xy=rMtx[0,1] 
 rMtx_xyzM.xz=rMtx[0,2] 
 rMtx_xyzM.yx=rMtx[1,0] 
 rMtx_xyzM.yy=rMtx[1,1] 
 rMtx_xyzM.yz=rMtx[1,2] 
 rMtx_xyzM.zx=rMtx[2,0] 
 rMtx_xyzM.zy=rMtx[2,1] 
 rMtx_xyzM.zz=rMtx[2,2] 
 tVec_xyzV=pyrosetta.rosetta.numeric.xyzVector_double_t() 
 tVec_xyzV.x=tVec[0] 
 tVec_xyzV.y=tVec[1] 
 tVec_xyzV.z=tVec[2] 
 return np.sqrt(rmsd_sq), rMtx_xyzM, tVec_xyzV 
  
def align_atoms_by_ndxs(pose1, 
 init_res1, 
 end_res1, 
 pose2, 
 init_res2, 
 end_res2, 
 atoms=["CA","C","O","N"]): 
 numRes=(end_res1-init_res1+1) 
 coorA=np.zeros(((len(atoms)*numRes),3), float) 
 coorB=np.zeros(((len(atoms)*numRes),3), float) 
 
 counter=0 
 for res in range (init_res1, (end_res1+1)): 
 for atom in atoms: 
 for dim in range(0,3): 
 coorA[counter,dim]=(pose1.residue(res).xyz(atom)[dim]) 
 counter+=1 
 
 counter=0 
 for res in range (init_res2, (end_res2+1)): 
 for atom in atoms: 
 for dim in range(0,3): 
 coorB[counter,dim]=(pose2.residue(res).xyz(atom)[dim]) 
 counter+=1 
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 rmsdVal, rMtx, tVec = rmsd_and_rosettaRotations_2_np_arrays(coorB, coorA) 
 pose1.apply_transform_Rx_plus_v(rMtx, tVec) 
 
 return rmsdVal 
 
 
class FullAtomRockPacker(pyrosetta.rosetta.protocols.moves.Mover): 
def __init__(self, rock_mover, pack_mover, scorefxn, filters, num_perturbations, max_rmsd, out_file_dir, unique_run_id, 
 core_max_sasa, 
 is_underpacked_func=lambda x: x < 0.10): 
 super(FullAtomRockPacker, self).__init__() 
 self.score_metric = pyrosetta.rosetta.core.simple_metrics.metrics.TotalEnergyMetric() 
 self.score_metric.set_scorefunction(scorefxn) 
 self.packing_metric = PackstatSimpleMetric() 
 self.is_underpacked = is_underpacked_func 
 self.rock_mover = rock_mover 
 self.pack_mover = pack_mover 
 self.max_rmsd = max_rmsd 
 self.filters = filters 
 self.num_perturbations = num_perturbations 
 self.out_file_dir = out_file_dir 
 self.unique_run_id = unique_run_id 
 self.small_rmsd_pert_num = 0.01 
 
def apply(self, pose): 
 in_pose_ss_contigous=pose.clone() 
 num_rockPack_randPert=self.num_perturbations 
 out_file_dir = self.out_file_dir 
 unique_run_id = self.unique_run_id 
 min_allowed_rock_packstat_score = 0.10 
 rockpack_reporting_frequency = 10 
 
 # for checking RMSD; needs to be created at apply time because it depends 
 # on the reference pose being right 
 rmsd_filter = RockPackRMSDFilter(reference_pose=pose, 
 residue_selectors=self.rock_mover.movable_residue_selectors, 
 max_rmsd=self.max_rmsd) 
 
 best_packed_perturbation=[] 
 ipose = in_pose_ss_contigous.clone() 
 self.pack_mover.apply(ipose) 
 
 max_allowed_rock_energy_score=self.score_metric.calculate(ipose) #Set the maximum score to the initial score 
 if debug: 
 ipose.dump_pdb("%s/debug/%s_rockpackInit_test_optSSPosition.pdb"%(out_file_dir, 
 unique_run_id)) 
 
 for icounter in range(num_rockPack_randPert): 
 tmp_test_ipose=ipose.clone() 
 
 # Random rigid body perturbation 
 self.rock_mover.apply(tmp_test_ipose) 
   
 # Assess RMSD by SS element and skip the perturbations if it is too large 
 if not rmsd_filter.apply(tmp_test_ipose): 
 continue 
   
 # Repack with small set of residues to evaluate packing 
 self.pack_mover.apply(tmp_test_ipose) 
 
 # Calc score after packing 
 tmp_cen_score=self.score_metric.calculate(tmp_test_ipose) 
   
 if (icounter%rockpack_reporting_frequency==0): 
 print("\n\nRockPerturbation %d"%icounter) 
 print("Best_packed_perturbation: ", best_packed_perturbation) 
   
 if ((len(best_packed_perturbation)==0) or 
 (tmp_cen_score<best_packed_perturbation[0])): 
 tmp_packstat_score=self.packing_metric.calculate(tmp_test_ipose) 
 if ((len(best_packed_perturbation)>0) and 
 self.is_underpacked(tmp_packstat_score)): 
 continue 
 if ((len(best_packed_perturbation)>0) and 
 (tmp_packstat_score<best_packed_perturbation[1])): 
 continue 
 
 print("Accepted: ", tmp_cen_score, tmp_packstat_score) 
 best_packed_perturbation = [tmp_cen_score, tmp_packstat_score, tmp_test_ipose.clone()] 
 if debug: 
 tmp_test_ipose.dump_pdb("%s/debug/%s_rockpack_%05d_%s_test_optSSPosition_best.pdb"%(out_file_dir, 
 unique_run_id, 
 icounter, 
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 unique_run_id)) 
 ipose=tmp_test_ipose.clone() 
 
 rolled_poses=None 
   
 if len(best_packed_perturbation)==0: 
 return 
 
 target_rockedPose_best = best_packed_perturbation[2] 
 if debug: 
 target_rockedPose_best.dump_pdb("%s/debug/%s_rockpackBest_test_optSSPosition.pdb"%(out_file_dir, 
 unique_run_id)) 
   
 chain_selectors = [self.rock_mover.fixed_residue_selector] + list(self.rock_mover.movable_residue_selectors) 
 inpose_split_by_ss=split_pose(pose, chain_selectors) 
 target_rockedPose_split_by_ss=split_pose(target_rockedPose_best, chain_selectors) 
 largest_chains_for_rocking = [(None, 1, target_rockedPose_split_by_ss[x].size(), 0) for x in range(1, 
1+len(target_rockedPose_split_by_ss))] 
 
 inpose_split_by_ss_optimized_position=[] 
 for indx in range(len(inpose_split_by_ss)): 
 inpose_split_by_ss_optimized_position.append(inpose_split_by_ss[indx+1].clone()) 
 
 if indx > 0: 
 assert(inpose_split_by_ss[indx+1].total_residue()== 
 (largest_chains_for_rocking[indx][2]-largest_chains_for_rocking[indx][1]+1 )) 
 
 tmp_rmsd=align_atoms_by_ndxs(inpose_split_by_ss_optimized_position[-1], 
 1, 
 inpose_split_by_ss_optimized_position[-1].total_residue(), 
 target_rockedPose_split_by_ss[indx+1], 
 largest_chains_for_rocking[indx][1], 
 largest_chains_for_rocking[indx][2], 
 atoms=["CA","C","O","N"]) 
 
 tmp_rmsd=tmp_rmsd-largest_chains_for_rocking[indx][3] 
 assert(tmp_rmsd<self.small_rmsd_pert_num) 
 
 in_pose_ss_rockOptimized_contigous=join_poses(inpose_split_by_ss_optimized_position) 
 if debug: 
 in_pose_ss_rockOptimized_contigous.dump_pdb("%s/debug/%s_test_optSSPosition.pdb"%(out_file_dir, 
 unique_run_id)) 
 
 pose.assign(in_pose_ss_rockOptimized_contigous) 
 print('Assigned to {}'.format(in_pose_ss_rockOptimized_contigous)) 
 
 
def parse_flags(): 
parser = argparse.ArgumentParser(description='Refines secondary structure position') 
 
parser.add_argument("--in_pdb_name", required=True, 
 type=str, help='Input PDB containing multiple chains to work on') 
 
parser.add_argument('--global_context_pdb', type=str, default=None, help='PDB containing the global context (e.g. 
receptor)') 
 
parser.add_argument("--num_rockPack_randPert", 
 type=int, dest="num_rockPack_randPert", default=1000) 
 
parser.add_argument("--max_rockPack_rmsd", 
 type=float, dest="max_rockPack_rmsd", default=3.0) 
 
parser.add_argument("--rockPack_chains", 
 type=str, nargs='*', dest="rockPack_chains", default=[]) 
 
parser.add_argument("--rockPack_low_resolution_refinement", 
 action='store_true', dest='rockPack_low_resolution_refinement', default=False, 
 help='Activates low resolution refinement of specific SS elements') 
 
parser.add_argument("--rockPack_disable_high_resolution_refinement", 
 action='store_false', dest='rockPack_high_resolution_refinement', 
 help='Deactivates high resolution refinement of specific SS elements') 
 
return parser.parse_args() 
 
# Constants 
debug = False 
layer_sasa_definitions={} 
layer_sasa_definitions["core"]=10.0 #% <=10.0-limbo 
layer_sasa_definitions["limbo"]=25.0 #% <=25.5 
layer_sasa_definitions["surf"]=40.0 #% <=40.0 
layer_sasa_definitions["interface"]=1.0 #% <=, This is chainge in SASA with and without context 
unique_run_id = str(uuid.uuid4()) 
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args = parse_flags() 
 
# Prepare debug folder 
if debug and not os.path.exists('debug'): 
os.mkdir('debug') 
 
# Initialize pyrosetta 
pyrosetta.init('-beta 1 -mute all') 
 
# Residue Selectors 
rockpack_selectors = [] 
for chain_str in args.rockPack_chains: 
selector = pyrosetta.rosetta.core.select.residue_selector.ChainSelector(chain_str) 
rockpack_selectors.append(selector) 
 
rockpack_all = pyrosetta.rosetta.core.select.residue_selector.OrResidueSelector() 
for sel in rockpack_selectors: 
rockpack_all.add_residue_selector(sel) 
 
fixed_selector = pyrosetta.rosetta.core.select.residue_selector.NotResidueSelector() 
fixed_selector.set_residue_selector(rockpack_all) 
 
# Load the pose 
pose = pyrosetta.pose_from_pdb(args.in_pdb_name) 
 
# Debug, print out residues 
residues = pyrosetta.rosetta.core.select.residue_selector.ResidueVector(fixed_selector.apply(pose)) 
for ix, selector in enumerate(rockpack_selectors): 
rockpack_residues = pyrosetta.rosetta.core.select.residue_selector.ResidueVector(selector.apply(pose)) 
 
if args.rockPack_low_resolution_refinement: 
print('Running low resolution rockPack ({} iterations)'.format(args.num_rockPack_randPert)) 
mover = RandomRoller(fixed_residue_selector=fixed_selector, movable_residue_selectors=rockpack_selectors, 
 distance_step=1.2, angle_step=8.0) 
 
# filters 
if args.global_context_pdb is None: 
 filters = [] 
else: 
 global_context_pose = pyrosetta.pose_from_file(args.global_context_pdb) 
 filters = [ClashCheckFilter(global_context_pose)] 
 
# Create the mover 
rocker = CentroidRocker(fixed_residue_selector=fixed_selector, 
 filters=filters, 
 mover=mover, 
 metric=CentroidScoreSimpleMetric(), 
 out_file_dir='.', 
 unique_run_id=str(uuid.uuid4()), 
 num_perturbations=args.num_rockPack_randPert) 
rocker.apply(pose) 
 
if args.rockPack_high_resolution_refinement: 
print('Running high resolution rockPack ({} iterations)'.format(args.num_rockPack_randPert)) 
 
# Full atom rockpack objects 
scorefxn_fa = pyrosetta.get_fa_scorefxn() 
 
# Movers 
fast_pack_mover = RockPackMover(packaas=['V', 'I', 'L'], scorefxn=scorefxn_fa) 
rock_mover = RandomRoller(fixed_residue_selector=fixed_selector, movable_residue_selectors=rockpack_selectors, 
 distance_step=1.2, angle_step=8.0) 
 
# Full atom rockpack 
rocker_fa = FullAtomRockPacker(filters=[], rock_mover=rock_mover, 
 pack_mover=fast_pack_mover, scorefxn=scorefxn_fa, 
 num_perturbations=args.num_rockPack_randPert, out_file_dir='.', unique_run_id=unique_run_id, 
 max_rmsd=args.max_rockPack_rmsd, core_max_sasa=layer_sasa_definitions['core']) 
 
# Run 
rocker_fa.apply(pose) 
 
pose.dump_pdb('output.pdb') 
 
####################################################################################################################### 
##################################################END################################################################## 
####################################################################################################################### 
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